



Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: a case control study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002604
Article Type:	Research
Date Submitted by the Author:	16-Jan-2013
Complete List of Authors:	Warren-Gash, Charlotte; UCL, Research Department of Infection & Population Health Geretti, Anna Maria; University of Liverpool, Institute of Infection and Global Health Hamilton, George; Royal Free London Foundation Trust, Department of Vascular Surgery Rakhit, Roby; Royal Free London Foundation Trust, Department of Cardiology Smeeth, Liam; London School of Hygiene and Tropical Medicine, Epidemiology and Population Health Hayward, Andrew; University College London, Infection and Population Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Infectious diseases, Cardiovascular medicine
Keywords:	Myocardial infarction < CARDIOLOGY, Epidemiology < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3 **Title** Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza
4
5 A H1N1 pandemic in London: a case control study
6
7

8
9 **Authors** Charlotte Warren-Gash¹, Anna Maria Geretti², George Hamilton³, Roby D. Rakhit⁴, Liam
10
11 Smeeth⁵, Andrew C. Hayward¹
12
13

14
15 **Affiliations**

16
17 ¹Centre for Infectious Disease Epidemiology, Research Department of Infection & Population Health,
18
19 UCL, London, UK
20

21
22 ² Institute of Infection and Global Health, University of Liverpool, UK
23

24
25 ³ Department of Vascular Surgery, Royal Free London Foundation Trust, London, UK
26

27
28 ⁴ Department of Cardiology, Royal Free London Foundation Trust, London, UK
29

30
31 ⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical
32
33 Medicine, London, UK
34
35

36
37 **Corresponding author**

38
39 Dr Charlotte Warren-Gash

40
41 Research Department of Infection & Population Health

42
43 1st Floor, Royal Free Hospital

44
45 Rowland Hill Street

46
47 London NW3 2PF

48
49 Email: c.warren-gash@ucl.ac.uk / charlotte.warren-gash@doctors.org.uk
50
51

52
53 Tel: 020 7794 0500 x36720 Fax: 020 7794 1224
54
55

56
57 **Word Count** Abstract 296, main text 2109 (excluding article summary, tables, figures, legends and refs)
58
59
60

ABSTRACT

Objective: To investigate recent respiratory and influenza-like illnesses in acute myocardial infarction patients compared to patients hospitalised for acute non vascular surgical conditions during the second wave of the 2009 influenza A H1N1 pandemic

Design: Case control study

Setting: Coronary care unit, acute cardiology and acute surgical admissions wards in a major teaching hospital in London, UK

Participants: 134 participants (70 cases and 64 controls) aged ≥ 40 years hospitalised for acute myocardial infarction and acute surgical conditions between 21/09/2009 and 28/02/2010, frequency-matched for gender, 5-year age-band and admission week

Primary exposure: Influenza-like illness (ILI - defined as feeling feverish with either cough or sore throat) within the last month. **Secondary exposures:** Acute respiratory illness within the last month not meeting ILI criteria; nasopharyngeal and throat swab positive for influenza virus

Results: 29 participants of 134 (21.6%) reported respiratory illness within the last month, of whom 13 (9.7%) had illnesses meeting ILI criteria. The most frequently reported category for timing of respiratory symptom onset was 8-14 days before admission (31.0% of illnesses). Cases were more likely than controls to report ILI – adjusted OR 3.17 (95% confidence interval 0.61-16.47) – as well as other key respiratory symptoms, and were less likely to have received influenza vaccination – adjusted OR 0.46 (95% CI, 0.19-1.12) – although differences were not statistically significant. No swabs were positive for influenza virus.

Conclusions: This study was supportive of the hypothesis that recent ILI was more common in patients hospitalised with acute myocardial infarction than with acute surgical conditions during the second wave of the influenza A H1N1 pandemic, and suggestive of a cardio-protective effect of influenza vaccination. It was, however, underpowered, partly because the age groups typically affected by acute

1
2
3 myocardial infarction had low rates of infection with the pandemic influenza strain compared to
4
5 seasonal influenza.
6
7
8
9

10 **ARTICLE SUMMARY**

11 **Article focus**

- 12 • Seasonal influenza can trigger cardiovascular complications but the cardiac effects of the 2009
13 influenza pandemic are less clear.
- 14 • We aimed to investigate recent influenza-like illness in patients hospitalised with acute
15 myocardial infarction and surgical conditions during the 2009 influenza pandemic in London.
16
17
18
19
20
21
22
23

24 **Key messages**

- 25 • 14.3% of patients hospitalised with acute myocardial infarction (cases) reported recent
26 influenza-like illness compared to 4.7% of patients hospitalised for acute surgical conditions
27 (controls)
- 28 • Cases were more likely than controls to report a range of recent respiratory symptoms and less
29 likely to have received influenza vaccination though differences were not statistically significant
30
31
32
- 33 • The median age of cases with acute myocardial infarction was 63.6 years, whereas the majority
34 of people infected with pandemic influenza strain nationally were young
35
36
37
38
39
40
41
42

43 **Strengths and limitations**

- 44 • The study was underpowered to detect an effect, partly due to low infection rates with the
45 pandemic influenza virus in age-groups typically affected by acute myocardial infarction, but it
46 will inform design of future similar studies
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Seasonal influenza can trigger cardiovascular complications and deaths in vulnerable populations, especially the elderly and those with underlying medical conditions¹. Evidence to support the hypothesis that seasonal influenza may trigger acute myocardial infarction comes from a range of observational studies incorporating the effects of different circulating influenza strains and subtypes². In a pandemic situation, however, when there is global spread of a novel influenza strain, clinical and demographic profiles of those affected may change dramatically.

The most recent influenza pandemic was caused by an influenza A H1N1 strain (H1N1pdm09) that emerged in Mexico and the United States in April 2009^{3,4}. The UK experienced several waves of infection with this novel strain - a first wave occurred in spring and summer 2009 followed by a second wave in the winter of 2009/10 and a post-pandemic wave in winter 2010/11⁵. Initial evidence from the first wave in the UK suggested that typical illnesses were mild and affected mainly children and young people⁶. The average age of cases increased over subsequent waves of the pandemic⁷ but it is unclear how this affected clinical illness profiles. Vaccination coverage did not reach high levels until the post-pandemic season.

There have been reports of myocarditis, myocardial injury and left ventricular systolic dysfunction in patients with severe H1N1pdm09^{8,9}. It has been suggested that H1N1pdm09 was associated with higher rates of extra-pulmonary complications than seasonal influenza¹⁰ but this is difficult to compare as surveillance of severe influenza-related disease was greatly enhanced during the pandemic. A recent mathematical modelling study estimated that globally there were 83,300 cardiovascular deaths associated with the first twelve months of H1N1pdm09 circulation in adults aged >17 years¹¹, but the contribution of myocardial infarction deaths to this figure is unknown.

1
2
3 In this study we aimed to investigate whether patients hospitalised for acute myocardial infarction
4 during the winter wave of the influenza A H1N1 pandemic were more likely than surgical patients to
5 have experienced recent influenza-like illness or acute respiratory illness, or to have concurrent PCR
6 positive influenza or evidence of influenza A IgA antibodies in sera.
7
8
9
10
11

12 13 **METHODS**

14 15 **Setting, design and participants**

16
17
18 This was an observational case control study carried out in hospital in-patients at the Royal Free London
19 NHS Foundation Trust between 21st September 2009 and 28th February 2010. Cases were patients aged
20 ≥40 years who had experienced an acute myocardial infarction (defined as a rise in troponin T with
21 ischaemic symptoms and/or typical ECG changes, or by angiographic evidence of acute coronary artery
22 thrombosis during primary percutaneous coronary intervention). Controls were patients aged ≥40 years
23 admitted with an acute surgical condition such as appendicitis, bowel or urinary obstruction and no
24 history of myocardial infarction within the past month, frequency matched for gender, age-group in 5
25 year age-bands and week of admission. All were English-speaking and able to provide written informed
26 consent.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 42 **Exposures**

43
44 The main exposure was recent influenza-like illness, defined as a history of feeling feverish with either
45 cough or sore throat within the last month. We also used the exposure recent acute respiratory
46 infection to capture a history of respiratory illness within the last month with any of the following
47 symptoms – fever, chills, dry cough, productive cough, myalgia, rhinorrhoea, blocked nose, sore throat,
48 wheeze, earache and fatigue – that did not meet criteria for influenza-like illness. Additional exposures
49 were nasopharyngeal and throat swabs testing positive for influenza by real-time polymerase chain
50
51
52
53
54
55
56
57
58
59
60

1
2
3 reaction (PCR), presence of IgA antibodies to influenza A in serum samples and self-reported influenza
4
5 vaccination status.
6
7

8 9 **Data sources and measurement**

10
11 We used a questionnaire to investigate recent respiratory and influenza-like illness as well as to collect
12
13 data on demographics, medical history and influenza vaccination status. Medical records were reviewed
14
15 for details of the current admission and to confirm data on potential confounding factors. Combined
16
17 nasopharyngeal and throat swabs were taken from each participant, placed in viral transport medium
18
19 and transported to the laboratory for storage at -80°C. Samples were tested for the presence of
20
21 influenza virus RNA using a validated in house real-time PCR with a lower limit of detection of 1 RNA
22
23 copy per reaction, as previously described¹². A single serum sample was taken for quantification of IgA
24
25 antibodies to influenza A as a marker of recent exposure. Serum samples were centrifuged, frozen at -
26
27 80°C and batch tested using a commercially available enzyme-linked immunosorbent assay (EIA) for
28
29 influenza A IgA (Biosupply UK, cat no. RE56501). Antibody concentrations were initially explored as a
30
31 continuous variable, then categorised into 'positive' (>12 U/ml), 'equivocal' (8-12 U/ml) and 'negative'
32
33 (>8 U/ml) categories based on standard laboratory thresholds. Equivocal results were dropped for
34
35 analyses.
36
37
38
39
40
41
42

43 **Statistical methods**

44
45 All analyses were carried out using Stata (*Stata Statistical Software: Release 12. College Station, TX:*
46
47 *StataCorp LP*). Baseline comparability between cases and controls was assessed with X^2 tests.
48
49 Characteristics of participants with and without missing data were also compared using X^2 tests to
50
51 assess any risk of bias associated with missing data. We used multivariable logistic regression analysis to
52
53 investigate associations between recent influenza-like illness or acute respiratory illness exposures and
54
55 case/ control status, controlling for age-group, gender, month of admission and influenza vaccination
56
57
58
59
60

1
2
3 status (all models) and other potential confounding factors. These were examined using a backwards
4
5 stepwise approach whereby factors independently associated with both exposure and outcome were
6
7 included in models and likelihood ratio tests used to assess the effect of removing each one
8
9
10 sequentially. If p values from likelihood ratio tests were <0.1 then factors were retained in the model.
11

12 13 **RESULTS**

14 15 **Characteristics of study participants**

16
17
18 134 participants were recruited, comprising 70 cases and 64 controls, for whom acceptance rates were
19
20 66% and 67% respectively. Median age was 63.6 years (IQR 53.3-72.6) and 21% of participants were
21
22 female. Cases were more likely to be of Asian or Asian British ethnicity (p=0.016), to have a previous
23
24 history of myocardial infarction (p=0.04) or a family history of myocardial infarction (p<0.001) than
25
26 controls. Of the 70 patients hospitalised for acute myocardial infarction, 48 (68.5%) met criteria for ST-
27
28 elevation myocardial infarction, 17 (24.3%) had a non ST-elevation myocardial infarction and in 5 (7.1%)
29
30 cases the subtype of myocardial infarction was unspecified. Control patients were admitted with a
31
32 range of acute non-vascular surgical presentations that included colorectal, urological and orthopaedic
33
34 conditions.
35
36
37
38
39
40

41 42 **Table 1**

43 44 **Timing of participants' admissions in relation to national influenza circulation**

45
46
47 A comparison of study participants' dates of admission with national rates of GP consultations for
48
49 influenza-like illness (ILI) based on RCGP surveillance data is shown in figure 1. The peak week for ILI
50
51 consultations in England was week 43 (ending 25th October 2009) when the rate was 42.8 per 100,000.
52
53
54 This was also the peak week for influenza virus circulation according to data from virological sentinel
55
56
57
58
59
60

1
2
3 surveillance schemes, when the proportion of positive samples reached 41.2%. Our recruitment period
4
5 spanned this period of peak influenza circulation.
6
7

8 9 **Figure 1**

10 **Recent respiratory and influenza-like illness**

11
12
13
14 17 cases (24.3%) and 12 controls (18.8%) reported respiratory illness in the month preceding hospital
15 admission. 13 illnesses – reported by 10 cases (14.3%) and 3 controls (4.7%) – met criteria for influenza-
16 like illness (defined as feeling feverish with cough and/or sore throat). The most frequently reported
17 category for the timing of respiratory symptom onset was 8-14 days before admission (31.0% of
18 illnesses). 4-7 days was the most frequently reported category for length of illness (37.9% of illnesses).
19
20 Symptom profiles of participants reporting recent respiratory illness are shown in figure 2. No swabs
21 tested positive for influenza virus nucleic acid. Serum samples were available on 113 of 134 participants
22 (84.3%). There were no significant differences in characteristics of participants with and without missing
23 serum samples (data not shown). 25 cases (43.1%) and 28 controls (50.9%) tested positive for serum
24 influenza A IgA antibodies. 62% of participants who were seropositive had received influenza
25 vaccination compared to 31% of seronegative participants.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Figure 2**

41
42
43 Cases were more likely to have reported influenza-like illness than controls – adjusted OR 3.17 (95%
44 confidence interval 0.61-16.47) – as well as other key respiratory illness symptoms, although differences
45 were not statistically significant. There was also a trend towards a protective effect of influenza
46 vaccination against myocardial infarction – adjusted OR 0.46 (95% CI, 0.19-1.12). Results from the
47
48
49
50
51
52 logistic regression analysis are summarised in table 2.
53
54

55 **Table 2**

DISCUSSION

The study was supportive of the hypothesis that recent respiratory and in particular influenza-like illnesses occurring during the second wave of the influenza A H1N1 pandemic were more common in patients hospitalised with acute myocardial infarction than with acute surgical conditions. Influenza vaccination was also associated with protection against myocardial infarction, although differences were not statistically significant. While we had hypothesised that more adults would be infected during the second pandemic wave due to the expected upwards shift in age distribution of infections, national rates of influenza-like illness remained low⁵, especially in age groups typically affected by acute myocardial infarction. The study was therefore underpowered to detect an effect, partly due to limited numbers of infections among participants.

Using self-reported recent respiratory and influenza-like illness as exposures introduced the possibility of reporting or recall bias. Nonetheless this method allows greater sensitivity to detect recent respiratory symptoms than relying on reports of medically attended illnesses, which comprise only a small minority of influenza cases¹³. As cases and controls were frequency matched on week of admission, external factors such as media coverage of the influenza pandemic should not have had a differential effect on respiratory illness reporting. We chose to test both nasopharyngeal and throat swabs to increase the sensitivity of virus detection. It was perhaps unsurprising, however, that none of the nasopharyngeal and throat swabs was positive for influenza virus given a) the low rates of infection in this age-group⁵ and b) that the majority of viral shedding in influenza occurs in the first 2-3 days after symptom onset¹⁴ whereas most reported respiratory symptoms in study participants occurred 8-14 days before admission. Based on our findings it seems unlikely that any delayed cardiac effect of influenza is linked to ongoing or prolonged virus replication or shedding in the respiratory tract. Influenza serology

1
2
3 is difficult to interpret in vaccinated participants as it not possible to distinguish antibody rises caused by
4 infection from those caused by vaccination. Validation of the IgA assay used suggests it has acceptable
5 sensitivity and specificity to detect recent seasonal influenza A infection¹⁵ but its effect with the
6 pandemic strain H1N1pdm09 is unclear. It has previously been noted that serological studies carried out
7 during the 2009 influenza pandemic were severely hampered by cross reactivity both with vaccine and
8 with seasonal influenza strains⁷.

9
10
11
12
13
14
15
16
17
18
19
20 Previous observational studies using large electronic primary care databases have found an association
21 between GP consultation for acute respiratory infection in the last month and risk of acute myocardial
22 infarction¹⁶⁻¹⁸. Although studies were conducted over different time periods, they encompassed the
23 effect of varying seasonal influenza strains. Our recent self-controlled case series study using linked
24 primary care and cardiac disease registry data from 3,927 patients also included acute respiratory
25 infection consultations occurring during the first wave of H1N1pdm09 circulation¹⁹. We found an
26 incidence ratio for acute myocardial infarction of 4.19 (95% confidence interval 3.18-5.53) in the first 1-3
27 days after acute respiratory infection, with the risk falling to baseline after 28 days¹⁹. Elderly people and
28 those consulting for an infection judged most likely to be due to influenza were at greatest risk. During
29 the 2009 influenza pandemic people with underlying cardiovascular disease were much more likely to
30 be hospitalised¹³ and to die²⁰ from a range of causes attributable to pandemic influenza. Although most
31 deaths from H1N1pdm09 occurred in younger people, this was partly a function of the age distribution
32 of infections: in the UK the case fatality rate in the elderly was much higher than in younger age-groups⁵
33 but overall numbers of deaths were small as few elderly people were infected.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Various biological mechanisms are proposed to underlie a relationship between influenza or acute
respiratory infection and myocardial infarction²¹. Acute respiratory infections may result in a host of

1
2
3 acute inflammatory and haemostatic effects leading to systemic inflammation, altered plasma viscosity,
4
5 coagulability and haemodynamic changes²² as well as promoting local endothelial dysfunction, coronary
6
7 inflammation and plaque rupture²³. Immobility associated with bed-rest and dehydration might
8
9 potentiate these processes.
10
11

12
13
14
15 In conclusion, this study suggests that recent ILI occurring during the 2009 influenza pandemic was more
16
17 common in AMI patients, so indirectly supports the hypothesis that, as with other influenza strains,
18
19 H1N1pdm09 could potentially trigger AMI in vulnerable groups. The population impact of H1N1pdm09
20
21 on rates of hospitalisations and deaths from myocardial infarction, however, is likely to have been
22
23 relatively low given the mismatch between the ages of those typically affected by H1N1pdm09 and
24
25 acute coronary events as well as the relatively mild clinical effects of this influenza strain.
26
27
28
29

30 31 **Acknowledgments**

32
33
34 We thank all patients who agreed to participate in this study and nurses on the cardiology and surgical
35
36 wards at the Royal Free Hospital who helped to identify potential participants. We acknowledge Mauli
37
38 Patel at the Royal Free Virology Laboratory who kindly processed, stored and tested samples.
39
40

41 42 **Contributors**

43
44
45 CWG conceived and designed the study, recruited participants, collected and analysed data and wrote
46
47 the manuscript. AMG, GH, RDR, LS and ACH assisted with study design. AMG provided laboratory
48
49 resources. CWG, AMG, RDR, LS and ACH interpreted results. AMG, GH, RDR, LS and ACH critically
50
51 revised the manuscript for intellectual content. LS and ACH provided supervision. All authors approved
52
53 the final version of the manuscript.
54
55
56
57
58
59
60

Funding statement

This work was funded by a Medical Research Council Clinical Research Training Fellowship for CWG, grant number G0800689. LS is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science, grant number 098504/Z/12/Z.

Competing interests statement

None declared

Data sharing statement

No additional data are available

References

1. Cox NJ, Subbarao K (1999) Influenza. *The Lancet* 354: 1277–1282.
2. Warren-Gash C, Smeeth L, Hayward AC (2009) Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. *The Lancet Infectious Diseases* 9: 601–610.
3. Swine influenza A (H1N1) infection in two children – Southern California, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 400–402.
4. Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 467–470.
5. Health Protection Agency (2010) Epidemiological report of pandemic (H1N1) 2009 in the United Kingdom: April 2009 - May 2010.
6. McLean E, Pebody RG, Campbell C, Chamberland M, Hawkins C, et al. (2010) Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol Infect* 138: 1531–1541.
7. Lagacé-Wiens PRS, Rubinstein E, Gumel A (2010) Influenza epidemiology – past, present, and future. *Crit Care Med* 38: e1–e9.
8. Chacko B, Peter JV, Pichamuthu K, Ramakrishna K, Moorthy M, et al. (2012) Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. *J Crit Care* 27: 106.e1–6.
9. Davoudi AR, Maleki AR, Beykmohammadi AR, Tayebi A (2012) Fulminant myopericarditis in an immunocompetent adult due to pandemic 2009 (H1N1) influenza A virus infection. *Scand J Infect Dis* 44: 470–472.
10. Lee N, Chan PKS, Lui GCY, Wong BCK, Sin WWY, et al. (2011) Complications and Outcomes of Pandemic 2009 Influenza A (H1N1) Virus Infection in Hospitalized Adults: How Do They Differ From Those in Seasonal Influenza? *J Infect Dis* 203: 1739–1747.
11. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, et al. (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *The Lancet Infectious Diseases* 12: 687–695.

12. Khanom AB, Velvin C, Hawrami K, Schutten M, Patel M, et al. (2011) Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care. *J Infect* 62: 52–58.
13. Campbell CNJ, Mytton OT, McLean EM, Rutter PD, Pebody RG, et al. (2010) Hospitalization in two waves of pandemic influenza A(H1N1) in England. *Epidemiology & Infection* 139: 1560–1569.
14. Lau LLH, Cowling BJ, Fang VJ, Chan K-H, Lau EHY, et al. (2010) Viral shedding and clinical illness in naturally acquired influenza virus infections. *J Infect Dis* 201: 1509–1516.
15. Rothbarth PH, Groen J, Bohnen AM, De Groot R, Osterhaus AD (1999) Influenza virus serology – a comparative study. *J Virol Methods* 78: 163–169.
16. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine* 351: 2611–2618.
17. Clayton TC, Thompson M, Meade TW (2008) Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. *Eur Heart J* 29: 96–103.
18. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H, et al. (1998) Acute respiratory-tract infections and risk of first-time acute myocardial infarction. *The Lancet* 351: 1467–1471.
19. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, et al. (2012) Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. *J Infect Dis* 206: 1652–1659.
20. Mytton OT, Rutter PD, Mak M, Stanton E, Sachedina N, et al. (2012) Mortality due to pandemic (H1N1) 2009 influenza in England: a comparison of the first and second waves. *Epidemiology & Infection* 140: 1533–1541.
21. Bazaz R, Marriott HM, Francis SE, Dockrell DH (2013) Mechanistic links between acute respiratory tract infections and acute coronary syndromes. *J Infect* 66: 1-17.
22. Harskamp RE, Van Ginkel MW (2008) Acute respiratory tract infections: a potential trigger for the acute coronary syndrome. *Annals of Medicine* 40: 121–128.
23. Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? *The Lancet* 349: 1391–1392.

Figure legends

Figure 1 Number of study participants admitted by influenza surveillance week compared to weekly ILI rates per 100,000 based on national RCGP surveillance data

Figure 2 Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory illness

1
2
3
4
5
6 **Tables**
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Characteristic	Category	Cases (n=70)	Controls (n=64)	P value
Age group	40-49	8 (11.4)	13 (20.3)	0.61
	50-59	19 (27.1)	18 (28.1)	
	60-69	19 (27.1)	15 (23.4)	
	70-79	17 (24.3)	11 (17.2)	
	80+	7 (10.0)	7 (10.9)	
Gender	Female	13 (18.6)	15 (23.4)	0.49
	Male	57 (81.4)	49 (76.6)	
Admission month	September	8 (11.4)	7 (10.9)	0.92
	October	12 (17.1)	15 (23.4)	
	November	15 (21.4)	14 (21.9)	
	December	10 (14.3)	10 (15.6)	
	January	14 (20.0)	11 (17.2)	
	February	11 (15.7)	7 (10.9)	
Ethnicity	Asian or Asian British	18 (25.7)	6 (9.4)	0.03
	Black or Black British	2 (2.9)	0 (0.0)	
	Mixed	0 (0.0)	1 (1.6)	
	White	50 (71.4)	57 (89.1)	
Smoker	No never	22 (31.4)	23 (35.9)	0.77
	Yes current	27 (38.6)	21 (32.8)	
	Yes ex	21 (30.0)	20 (31.3)	
Diabetes	No	56 (80.0)	52 (81.3)	0.86
	Yes	14 (20.0)	12 (18.8)	
Hypertension	No	33 (47.1)	38 (59.4)	0.16
	Yes	37 (52.9)	26 (40.6)	
Hypercholesterolaemia	No	36 (51.4)	36 (56.3)	0.58
	Yes	34 (48.6)	28 (43.8)	
Personal history of AMI	No	56 (80.0)	59 (92.2)	0.04
	Yes	14 (20.0)	5 (7.8)	
Personal history of stroke	No	69 (98.6)	60 (93.8)	0.14
	Yes	1 (1.4)	4 (6.3)	
Family history of AMI	No	27 (38.6)	45 (70.3)	<0.001
	Yes	43 (61.4)	19 (29.7)	
Family history of stroke	No	65 (92.9)	58 (90.6)	0.64
	Yes	5 (7.1)	6 (9.4)	
BMI category	18.5-24.9	20 (30.8)	23 (39.0)	0.41
	25.0-29.9	36 (55.4)	24 (40.7)	
	30.0-39.9	8 (12.3)	10 (17.0)	
	40.0-max	1 (1.5)	2 (3.4)	
Influenza vaccination status [†]	Vaccinated	30 (42.9)	29 (45.3)	0.78
	Unvaccinated	40 (57.1)	35 (54.7)	

Table 1 Characteristics of study participants (n=134)

[†]'Vaccinated' refers to receiving influenza vaccination in the current vaccination year (ie since September 2009). All other years were classed as 'unvaccinated' as the H1N1pdm09 strain was not represented in the vaccine


Exposure variable	Prevalence – cases, n(%)	Prevalence – controls, n(%)	Unadjusted odds ratio (95% CI)	Adjusted odds ratio* (95% CI)
1. Respiratory illness	17 (24.3)	12 (18.8)	1.39 (0.60-3.19)	1.39 (0.56-3.47)
2. Influenza-like illness	10 (14.3)	3 (4.7)	3.39 (0.89-12.92)	3.17 (0.61-16.47)
3. Fever	11 (15.7)	4 (6.3)	2.80 (0.84-9.28)	2.42 (0.54-10.98)
4. Cough	21 (30.0)	10 (15.6)	2.31 (0.99-5.40)	2.04 (0.76-5.47)
5. Sore throat	10 (14.3)	8 (12.5)	1.17 (0.43-3.17)	1.43 (0.44-4.69)
6. Influenza A IgA antibodies [‡]	25 (46.3)	28 (54.9)	0.71 (0.33-1.53)	0.82 (0.34-2.00)

Table 2 Odds ratios for the association between acute myocardial infarction and various respiratory illness exposure variables, unadjusted and adjusted

* Adjustments were made for age-group, gender, month of admission and influenza vaccination status (all exposures), family history of myocardial infarction (exposures 2, 3, 4 & 5) and personal history of myocardial infarction (exposures 2, 3, 4 & 5)


[‡]Note that n=105 (54 cases and 51 controls) for influenza antibodies where 8 equivocal results were excluded, compared to n=134 (70 cases and 64 controls) for all other exposures.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Number of study participants admitted by influenza surveillance week compared to weekly ILI rates per 100,000 based on national RCGP surveillance data
264x158mm (96 x 96 DPI)

review only



Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory illness
264x158mm (96 x 96 DPI)

Review only

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation	Reported on page no.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	5
		(b) For matched studies, give matching criteria and the number of controls per case	Frequency matching criteria given on p5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	Study size based on numbers of eligible patients hospitalised during the influenza circulation period
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how matching of cases and controls was addressed	N/A

		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	Data not systematically collected but reasons for non-participation include lack of time and feeling unwell during admission
		(c) Consider use of a flow diagram	Not done as no follow up with this study design. Fig 1 shows recruitment over time.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1 and p8
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: a case control study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002604.R1
Article Type:	Research
Date Submitted by the Author:	07-Mar-2013
Complete List of Authors:	Warren-Gash, Charlotte; UCL, Research Department of Infection & Population Health Geretti, Anna Maria; University of Liverpool, Institute of Infection and Global Health Hamilton, George; Royal Free London Foundation Trust, Department of Vascular Surgery Rakhit, Roby; Royal Free London Foundation Trust, Department of Cardiology Smeeth, Liam; London School of Hygiene and Tropical Medicine, Epidemiology and Population Health Hayward, Andrew; University College London, Infection and Population Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Infectious diseases, Cardiovascular medicine
Keywords:	Myocardial infarction < CARDIOLOGY, Epidemiology < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3 **Title** Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza
4
5 A H1N1 pandemic in London: a case control study
6
7

8
9 **Authors** Charlotte Warren-Gash¹, Anna Maria Geretti², George Hamilton³, Roby D. Rakhit⁴, Liam
10
11 Smeeth⁵, Andrew C. Hayward¹
12
13

14
15 **Affiliations**

16
17 ¹Centre for Infectious Disease Epidemiology, Research Department of Infection & Population Health,
18
19 UCL, London, UK
20
21

22 ² Institute of Infection and Global Health, University of Liverpool, UK
23

24 ³ Department of Vascular Surgery, Royal Free London Foundation Trust, London, UK
25

26 ⁴ Department of Cardiology, Royal Free London Foundation Trust, London, UK
27

28 ⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical
29
30 Medicine, London, UK
31
32

33
34
35 **Corresponding author**

36
37 Dr Charlotte Warren-Gash

38
39 Research Department of Infection & Population Health

40
41
42 1st Floor, Royal Free Hospital

43
44 Rowland Hill Street

45
46 London NW3 2PF

47
48 Email: c.warren-gash@ucl.ac.uk / charlotte.warren-gash@doctors.org.uk
49
50

51
52
53 Tel: 020 7794 0500 x36720 Fax: 020 7794 1224
54

55
56 **Word Count** Abstract 296, main text 2389 (excluding article summary, tables, figures, legends and refs)
57
58
59
60

ABSTRACT

Objective: To investigate recent respiratory and influenza-like illnesses in acute myocardial infarction patients compared to patients hospitalised for acute non vascular surgical conditions during the second wave of the 2009 influenza A H1N1 pandemic

Design: Case control study

Setting: Coronary care unit, acute cardiology and acute surgical admissions wards in a major teaching hospital in London, UK

Participants: 134 participants (70 cases and 64 controls) aged ≥ 40 years hospitalised for acute myocardial infarction and acute surgical conditions between 21/09/2009 and 28/02/2010, frequency-matched for gender, 5-year age-band and admission week

Primary exposure: Influenza-like illness (ILI - defined as feeling feverish with either cough or sore throat) within the last month. **Secondary exposures:** Acute respiratory illness within the last month not meeting ILI criteria; nasopharyngeal and throat swab positive for influenza virus

Results: 29 participants of 134 (21.6%) reported respiratory illness within the last month, of whom 13 (9.7%) had illnesses meeting ILI criteria. The most frequently reported category for timing of respiratory symptom onset was 8-14 days before admission (31.0% of illnesses). Cases were more likely than controls to report ILI – adjusted OR 3.17 (95% confidence interval 0.61-16.47) – as well as other key respiratory symptoms, and were less likely to have received influenza vaccination – adjusted OR 0.46 (95% CI, 0.19-1.12) – although differences were not statistically significant. No swabs were positive for influenza virus.

Conclusions: Point estimates suggested that recent ILI was more common in patients hospitalised with acute myocardial infarction than with acute surgical conditions during the second wave of the influenza A H1N1 pandemic, and influenza vaccination was associated with cardio-protection, although findings were not statistically significant. The study was underpowered, partly because the age groups typically

1
2
3 affected by acute myocardial infarction had low rates of infection with the pandemic influenza strain
4
5 compared to seasonal influenza.
6
7
8
9

10 **ARTICLE SUMMARY**

11 **Article focus**

- 12 • Seasonal influenza can trigger cardiovascular complications but the cardiac effects of the 2009
13 influenza pandemic are less clear.
- 14 • We aimed to investigate recent influenza-like illness in patients hospitalised with acute
15 myocardial infarction and surgical conditions during the 2009 influenza pandemic in London.
16
17
18
19
20
21
22
23

24 **Key messages**

- 25 • 14.3% of patients hospitalised with acute myocardial infarction (cases) reported recent
26 influenza-like illness compared to 4.7% of patients hospitalised for acute surgical conditions
27 (controls)
- 28 • Cases were more likely than controls to report a range of recent respiratory symptoms and less
29 likely to have received influenza vaccination though differences were not statistically significant
30
31
32
- 33 • The median age of cases with acute myocardial infarction was 63.6 years, whereas the majority
34 of people infected with pandemic influenza strain nationally were young
35
36
37
38
39
40
41
42

43 **Strengths and limitations**

- 44 • The study was underpowered to detect an effect, partly due to low infection rates with the
45 pandemic influenza virus in age-groups typically affected by acute myocardial infarction, but it
46 will inform design of future similar studies
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Seasonal influenza can trigger cardiovascular complications and deaths in vulnerable populations, especially the elderly and those with underlying medical conditions¹. Evidence to support the hypothesis that seasonal influenza may trigger acute myocardial infarction comes from a range of observational studies incorporating the effects of different circulating influenza strains and subtypes². In a pandemic situation, however, when there is global spread of a novel influenza strain, clinical and demographic profiles of those affected may change dramatically.

The most recent influenza pandemic was caused by an influenza A H1N1 strain (H1N1pdm09) that emerged in Mexico and the United States in April 2009^{3,4}. The UK experienced several waves of infection with this novel strain - a first wave occurred in spring and summer 2009 followed by a second wave in the winter of 2009/10 and a post-pandemic wave in winter 2010/11⁵. Initial evidence from the first wave in the UK suggested that typical illnesses were mild and affected mainly children and young people⁶. The average age of cases increased over subsequent waves of the pandemic⁷ but it is unclear how this affected clinical illness profiles. Vaccination coverage did not reach high levels until the post-pandemic season.

There have been reports of myocarditis, myocardial injury and left ventricular systolic dysfunction, which may be reversible, in patients with severe H1N1pdm09^{8,9}. It has been suggested that H1N1pdm09 was associated with higher rates of extra-pulmonary complications than seasonal influenza¹⁰ but this is difficult to compare as surveillance of severe influenza-related disease was greatly enhanced during the pandemic. A recent mathematical modelling study estimated that globally there were 83,300 cardiovascular deaths associated with the first twelve months of H1N1pdm09 circulation in adults aged >17 years¹¹, but the contribution of myocardial infarction deaths to this figure is unknown.

1
2
3 In this study we aimed to investigate whether patients hospitalised for acute myocardial infarction
4 during the winter wave of the influenza A H1N1 pandemic were more likely than surgical patients to
5 have experienced recent influenza-like illness or acute respiratory illness, or to have concurrent PCR
6 positive influenza or evidence of influenza A IgA antibodies in sera.
7
8
9
10
11
12

13 **METHODS**

14 **Setting, design and participants**

15
16
17
18
19
20 This was an observational case control study carried out in hospital in-patients at the Royal Free London
21 NHS Foundation Trust between 21st September 2009 and 28th February 2010. Cases were patients aged
22 ≥40 years who had experienced an acute myocardial infarction (defined as a rise in troponin T with
23 ischaemic symptoms and/or typical ECG changes, or by angiographic evidence of acute coronary artery
24 thrombosis during primary percutaneous coronary intervention). Controls were patients aged ≥40 years
25 admitted with an acute surgical condition such as appendicitis, bowel or urinary obstruction and no
26 history of myocardial infarction within the past month. These patients were chosen as controls because
27 their admissions were considered unlikely to be influenced by recent influenza-like illness. Cases and
28 controls were frequency matched for gender, age-group in 5 year age-bands and week of admission. All
29 were English-speaking and able to provide written informed consent. The study size was based on
30 numbers of eligible patients hospitalised during the influenza circulation period.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Exposures**

47
48
49 The main exposure was recent influenza-like illness, defined as a history of feeling feverish with either
50 cough or sore throat within the last month. We also used the exposure recent acute respiratory
51 infection to capture a history of respiratory illness within the last month with any of the following
52 symptoms – fever, chills, dry cough, productive cough, myalgia, rhinorrhoea, blocked nose, sore throat,
53
54
55
56
57
58
59
60

1
2
3 wheeze, earache and fatigue – that did not meet criteria for influenza-like illness. Additional exposures
4
5 were nasopharyngeal and throat swabs testing positive for influenza by real-time polymerase chain
6
7 reaction (PCR), presence of IgA antibodies to influenza A in serum samples and self-reported influenza
8
9 vaccination status.
10

11 12 13 **Data sources and measurement**

14
15
16 We used a questionnaire to investigate recent respiratory and influenza-like illness as well as to capture
17
18 data on demographics, medical history and influenza vaccination status. Information on influenza
19
20 vaccination status was collected as 'vaccinated this year (from September 2009)', 'vaccinated last year
21
22 (September 2008 - August 2009)', 'vaccinated 2-5 years ago', 'vaccinated >5 years ago' and 'never
23
24 vaccinated'. Vaccination status was then re-categorised as a binary variable comprising 'vaccinated this
25
26 year' and 'unvaccinated', which included all other categories, to recognise that vaccinations in previous
27
28 seasons would not protect against the new circulating pandemic influenza strain. Medical records were
29
30 reviewed for details of the current admission and to confirm data on potential confounding factors.
31
32 Combined nasopharyngeal and throat swabs were taken from each participant, placed in viral transport
33
34 medium and transported to the laboratory for storage at -80°C. Samples were tested for the presence of
35
36 influenza virus RNA using a validated in house real-time PCR with a lower limit of detection of 1 RNA
37
38 copy per reaction, as previously described¹². A single serum sample was taken for quantification of IgA
39
40 antibodies to influenza A as a marker of recent exposure (as IgA levels peak at around 2 weeks after
41
42 exposure and reach baseline by around 4-6 weeks). Serum samples were centrifuged, frozen at -80°C
43
44 and batch tested using a commercially available enzyme-linked immunosorbent assay (EIA) for influenza
45
46 A IgA (Biosupply UK, cat no. RE56501). Antibody concentrations were initially explored as a continuous
47
48 variable, then categorised into 'positive' (>12 U/ml), 'equivocal' (8-12 U/ml) and 'negative' (>8 U/ml)
49
50 categories based on standard laboratory thresholds. Equivocal results were dropped for analyses.
51
52
53
54
55
56
57
58
59
60

Statistical methods

All analyses were carried out using Stata (*Stata Statistical Software: Release 12. College Station, TX: StataCorp LP*). Baseline comparability between cases and controls was assessed with X^2 tests.

Characteristics of participants with and without missing data were also compared using X^2 tests to assess any risk of bias associated with missing data. We used multivariable logistic regression analysis to investigate associations between recent influenza-like illness or acute respiratory illness exposures and case/ control status, controlling for the frequency-matching factors age-group, gender and month of admission and influenza vaccination status as an a priori confounder (all models) as well as for other potential confounding factors. An additional multivariable model in which influenza vaccination status was the main exposure was generated using the same approach. Potential confounders were examined using a backwards stepwise approach whereby factors independently associated with both exposure and outcome were included in models and likelihood ratio tests used to assess the effect of removing each one sequentially. If p values from likelihood ratio tests were <0.1 then factors were retained in the model.

RESULTS

Characteristics of study participants

134 participants were recruited, who comprised 70 cases from 106 approached (acceptance rate 66%) and 64 controls from 95 approached (acceptance rate 67%). Reasons for non-participation included lack of time, unwillingness to experience additional procedures and feeling tired or unwell. The median age of participants was 63.6 years (IQR 53.3-72.6) and 21% were female. Cases were more likely to be of Asian or Asian British ethnicity ($p=0.016$), to have a previous history of myocardial infarction ($p=0.04$) or a family history of myocardial infarction ($p<0.001$) than controls. Of the 70 patients hospitalised for acute myocardial infarction, 48 (68.5%) met criteria for ST-elevation myocardial infarction, 17 (24.3%)

1
2
3 had a non ST-elevation myocardial infarction and in 5 (7.1%) cases the subtype of myocardial infarction
4
5 was unspecified. Control patients were admitted with a range of acute non-vascular surgical
6
7 presentations that included colorectal, urological and orthopaedic conditions.
8
9

10
11 **Table 1**

12
13
14 **Timing of participants' admissions in relation to national influenza circulation**

15
16
17 A comparison of study participants' dates of admission with national rates of GP consultations for
18
19 influenza-like illness (ILI) based on RCGP surveillance data is shown in figure 1. The peak week for ILI
20
21 consultations in England was week 43 (ending 25th October 2009) when the rate was 42.8 per 100,000.
22
23 This was also the peak week for influenza virus circulation according to data from virological sentinel
24
25 surveillance schemes, when the proportion of positive samples reached 41.2%. Our recruitment period
26
27 spanned this period of peak influenza circulation.
28
29

30
31
32 **Figure 1**

33
34 **Recent respiratory and influenza-like illness**

35
36
37 17 cases (24.3%) and 12 controls (18.8%) reported respiratory illness in the month preceding hospital
38
39 admission. 13 illnesses – reported by 10 cases (14.3%) and 3 controls (4.7%) – met criteria for influenza-
40
41 like illness (defined as feeling feverish with cough and/or sore throat). The most frequently reported
42
43 category for the timing of respiratory symptom onset was 8-14 days before admission (31.0% of
44
45 illnesses). 4-7 days was the most frequently reported category for length of illness (37.9% of illnesses).
46
47 Symptom profiles of participants reporting recent respiratory illness are shown in figure 2. No swabs
48
49 tested positive for influenza virus nucleic acid. Serum samples were available on 113 of 134 participants
50
51 (84.3%). There were no significant differences in characteristics of participants with and without missing
52
53 serum samples (data not shown). 25 cases (43.1%) and 28 controls (50.9%) tested positive for serum
54
55
56
57
58
59
60

1
2
3 influenza A IgA antibodies. 62% of participants who were seropositive had received influenza
4
5 vaccination during the study period compared to 31% of seronegative participants. Overall 44.0% of
6
7 participants were vaccinated. The proportion of participants recruited in each month who were
8
9 vaccinated increased from 0% in September 2009, to 29.6% in October 2009, 44.8% in November 2009,
10
11 55.0% in December 2009, 72.0% in January 2010 and was 50% in February 2010.
12
13

14 15 16 **Figure 2**

17
18 Cases were more likely to have reported influenza-like illness than controls – adjusted OR 3.17 (95%
19
20 confidence interval 0.61-16.47) – as well as other key respiratory illness symptoms, although differences
21
22 were not statistically significant. Results from this logistic regression analysis are summarised in table 2.
23
24 There was also a trend towards a protective effect of influenza vaccination against myocardial infarction
25
26 – adjusted OR 0.46 (95% CI, 0.19-1.12) – after controlling for age-group, gender, month of admission and
27
28 personal history of AMI.
29
30
31

32 33 **Table 2**

34 35 36 **DISCUSSION**

37
38
39 The study was supportive of the hypothesis that recent respiratory and in particular influenza-like
40
41 illnesses occurring during the second wave of the influenza A H1N1 pandemic were more common in
42
43 patients hospitalised with acute myocardial infarction than with acute surgical conditions. Influenza
44
45 vaccination was also associated with protection against myocardial infarction, although differences were
46
47 not statistically significant. While we had hypothesised that more adults would be infected during the
48
49 second pandemic wave due to the expected upwards shift in age distribution of infections, national
50
51 rates of influenza-like illness remained low⁵, especially in age groups typically affected by acute
52
53 myocardial infarction. The study was therefore underpowered to detect an effect, partly due to limited
54
55 numbers of infections among participants.
56
57
58
59
60

1
2
3
4
5
6
7 Using self-reported recent respiratory and influenza-like illness as exposures introduced the possibility
8
9 of reporting or recall bias. Nonetheless this method allows greater sensitivity to detect recent
10
11 respiratory symptoms than relying on reports of medically attended illnesses, which comprise only a
12
13 small minority of influenza cases¹³. As cases and controls were frequency matched on week of
14
15 admission, external factors such as media coverage of the influenza pandemic should not have had a
16
17 differential effect on respiratory illness reporting. We chose to test both nasopharyngeal and throat
18
19 swabs to increase the sensitivity of virus detection. It was perhaps unsurprising, however, that none of
20
21 the nasopharyngeal and throat swabs was positive for influenza virus given a) the low rates of infection
22
23 in this age-group⁵ and b) that the majority of viral shedding in influenza occurs in the first 2-3 days after
24
25 symptom onset¹⁴ whereas most reported respiratory symptoms in study participants occurred 8-14 days
26
27 before admission. Based on our findings it seems unlikely that any delayed cardiac effect of influenza is
28
29 linked to ongoing or prolonged virus replication or shedding in the respiratory tract. Influenza serology
30
31 is difficult to interpret in vaccinated participants as it not possible to distinguish antibody rises caused by
32
33 infection from those caused by vaccination. Validation of the IgA assay used suggests it has acceptable
34
35 sensitivity and specificity to detect recent seasonal influenza A infection¹⁵ but its effect with the
36
37 pandemic strain H1N1pdm09 is unclear. It has previously been noted that serological studies carried out
38
39 during the 2009 influenza pandemic were severely hampered by cross reactivity both with vaccine and
40
41 with seasonal influenza strains⁷.

42
43
44
45
46
47
48
49
50 Previous observational studies using large electronic primary care databases have found an association
51
52 between GP consultation for acute respiratory infection in the last month and risk of acute myocardial
53
54 infarction¹⁶⁻¹⁸. Although studies were conducted over different time periods, they encompassed the
55
56 effect of varying seasonal influenza strains. Our recent self-controlled case series study using linked
57
58
59
60

1
2
3 primary care and cardiac disease registry data from 3,927 patients also included acute respiratory
4
5 infection consultations occurring during the first wave of H1N1pdm09 circulation¹⁹. We found an
6
7 incidence ratio for acute myocardial infarction of 4.19 (95% confidence interval 3.18-5.53) in the first 1-3
8
9 days after acute respiratory infection, with the risk falling to baseline after 28 days¹⁹. Elderly people and
10
11 those consulting for an infection judged most likely to be due to influenza were at greatest risk. During
12
13 the 2009 influenza pandemic people with underlying cardiovascular disease were much more likely to
14
15 be hospitalised¹³ and to die²⁰ from a range of causes attributable to pandemic influenza. Although most
16
17 deaths from H1N1pdm09 occurred in younger people, this was partly a function of the age distribution
18
19 of infections: in the UK the case fatality rate in the elderly was much higher than in younger age-groups⁵
20
21 but overall numbers of deaths were small as few elderly people were infected.
22
23
24
25
26
27

28 Various biological mechanisms are proposed to underlie a relationship between influenza or acute
29
30 respiratory infection and myocardial infarction²¹. Acute respiratory infections may result in a host of
31
32 acute inflammatory and haemostatic effects leading to systemic inflammation, altered plasma viscosity,
33
34 coagulability and haemodynamic changes²² as well as promoting local endothelial dysfunction, coronary
35
36 inflammation and plaque rupture²³. Immobility associated with bed-rest and dehydration might
37
38 potentiate these processes.
39
40
41
42
43
44

45 In conclusion, this study suggests that recent ILI occurring during the 2009 influenza pandemic was more
46
47 common in AMI patients. Taken in the context of previous work, this helps to support the hypothesis
48
49 that, as with other influenza strains, H1N1pdm09 could potentially trigger AMI in vulnerable groups. It
50
51 is likely, however, that the effect is not specific to influenza and could have also been due to other
52
53 viruses circulating at the time. The population impact of H1N1pdm09 on rates of hospitalisations and
54
55 deaths from myocardial infarction is also likely to have been relatively low given the mismatch between
56
57
58
59
60

1
2
3 the ages of those typically affected by H1N1pdm09 and acute coronary events as well as the relatively
4
5 mild clinical effects of this influenza strain.
6
7
8
9

10 **Acknowledgments**

11
12
13 We thank all patients who agreed to participate in this study and nurses on the cardiology and surgical
14
15 wards at the Royal Free Hospital who helped to identify potential participants. We acknowledge Mauli
16
17 Patel at the Royal Free Virology Laboratory who kindly processed, stored and tested samples.
18
19

20 **Contributors**

21
22
23
24 CWG conceived and designed the study, recruited participants, collected and analysed data and wrote
25
26 the manuscript. AMG, GH, RDR, LS and ACH assisted with study design. AMG provided laboratory
27
28 resources. CWG, AMG, RDR, LS and ACH interpreted results. AMG, GH, RDR, LS and ACH critically
29
30 revised the manuscript for intellectual content. LS and ACH provided supervision. All authors approved
31
32 the final version of the manuscript.
33
34
35

36 **Funding statement**

37
38
39 This work was funded by a Medical Research Council Clinical Research Training Fellowship for CWG,
40
41 grant number G0800689. LS is supported by a Wellcome Trust Senior Research Fellowship in Clinical
42
43 Science, grant number 098504/Z/12/Z.
44
45
46

47 **Competing interests statement**

48
49
50 None declared
51
52

53 **Data sharing statement**

54
55
56 No additional data are available
57
58
59
60

References

1. Cox NJ, Subbarao K (1999) Influenza. *The Lancet* 354: 1277–1282.
2. Warren-Gash C, Smeeth L, Hayward AC (2009) Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. *The Lancet Infectious Diseases* 9: 601–610.
3. Swine influenza A (H1N1) infection in two children – Southern California, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 400–402.
4. Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 467–470.
5. Health Protection Agency (2010) Epidemiological report of pandemic (H1N1) 2009 in the United Kingdom: April 2009 - May 2010.
6. McLean E, Pebody RG, Campbell C, Chamberland M, Hawkins C, et al. (2010) Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol Infect* 138: 1531–1541.
7. Lagacé-Wiens PRS, Rubinstein E, Gumel A (2010) Influenza epidemiology – past, present, and future. *Crit Care Med* 38: e1–e9.
8. Chacko B, Peter JV, Pichamuthu K, Ramakrishna K, Moorthy M, et al. (2012) Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. *J Crit Care* 27: 106.e1–6.
9. Martin SS, Hollingsworth CL, Norfolk SG, Wolfe CR, Hollingsworth JW. (2010) Reversible cardiac dysfunction associated with pandemic 2009 influenza A (H1N1). *Chest* 137: 1195–7.
10. Lee N, Chan PKS, Lui GCY, Wong BCK, Sin WWY, et al. (2011) Complications and Outcomes of Pandemic 2009 Influenza A (H1N1) Virus Infection in Hospitalized Adults: How Do They Differ From Those in Seasonal Influenza? *J Infect Dis* 203: 1739–1747.
11. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, et al. (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *The Lancet Infectious Diseases* 12: 687–695.
12. Khanom AB, Velvin C, Hawrami K, Schutten M, Patel M, et al. (2011) Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care. *J Infect* 62: 52–58.
13. Campbell CNJ, Mytton OT, McLean EM, Rutter PD, Pebody RG, et al. (2010) Hospitalization in two waves of pandemic influenza A(H1N1) in England. *Epidemiology & Infection* 139: 1560–1569.
14. Lau LLH, Cowling BJ, Fang VJ, Chan K-H, Lau EHY, et al. (2010) Viral shedding and clinical illness in naturally acquired influenza virus infections. *J Infect Dis* 201: 1509–1516.
15. Rothbarth PH, Groen J, Bohnen AM, De Groot R, Osterhaus AD (1999) Influenza virus serology – a comparative study. *J Virol Methods* 78: 163–169.
16. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine* 351: 2611–2618.
17. Clayton TC, Thompson M, Meade TW (2008) Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. *Eur Heart J* 29: 96–103.
18. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H, et al. (1998) Acute respiratory-tract infections and risk of first-time acute myocardial infarction. *The Lancet* 351: 1467–1471.
19. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, et al. (2012) Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. *J Infect Dis* 206: 1652–1659.
20. Mytton OT, Rutter PD, Mak M, Stanton E, Sachedina N, et al. (2012) Mortality due to pandemic (H1N1) 2009 influenza in England: a comparison of the first and second waves. *Epidemiology & Infection* 140: 1533–1541.

- 1
- 2
- 3
- 4 21. Bazaz R, Marriott HM, Francis SE, Dockrell DH (2013) Mechanistic links between acute respiratory
- 5 tract infections and acute coronary syndromes. *J Infect* 66: 1-17.
- 6
- 7 22. Harskamp RE, Van Ginkel MW (2008) Acute respiratory tract infections: a potential trigger for the
- 8 acute coronary syndrome. *Annals of Medicine* 40: 121–128.
- 9
- 10 23. Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: does acute endothelial
- 11 dysfunction provide a link? *The Lancet* 349: 1391–1392.
- 12

13 **Figure legends**

14 **Figure 1** Number of study participants admitted by influenza surveillance week compared to weekly ILI
15 rates per 100,000 based on national RCGP surveillance data
16
17

18 **Figure 2** Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory
19 illness
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Characteristic	Category	Cases (n=70)	Controls (n=64)	P value
Age group	40-49	8 (11.4)	13 (20.3)	0.61
	50-59	19 (27.1)	18 (28.1)	
	60-69	19 (27.1)	15 (23.4)	
	70-79	17 (24.3)	11 (17.2)	
	80+	7 (10.0)	7 (10.9)	
Gender	Female	13 (18.6)	15 (23.4)	0.49
	Male	57 (81.4)	49 (76.6)	
Admission month	September	8 (11.4)	7 (10.9)	0.92
	October	12 (17.1)	15 (23.4)	
	November	15 (21.4)	14 (21.9)	
	December	10 (14.3)	10 (15.6)	
	January	14 (20.0)	11 (17.2)	
	February	11 (15.7)	7 (10.9)	
Ethnicity	Asian or Asian British	18 (25.7)	6 (9.4)	0.03
	Black or Black British	2 (2.9)	0 (0.0)	
	Mixed	0 (0.0)	1 (1.6)	
	White	50 (71.4)	57 (89.1)	
BMI category	18.5-24.9	20 (30.8)	23 (39.0)	0.41
	25.0-29.9	36 (55.4)	24 (40.7)	
	30.0-39.9	8 (12.3)	10 (17.0)	
	40.0-max	1 (1.5)	2 (3.4)	
Smoker	No never	22 (31.4)	23 (35.9)	0.77
	Yes current	27 (38.6)	21 (32.8)	
	Yes ex	21 (30.0)	20 (31.3)	
Past medical history	Hypercholesterolaemia*	34 (48.6)	28 (43.8)	0.58
	Diabetes	14 (20.0)	12 (18.8)	
	Hypertension	37 (52.9)	26 (40.6)	
	AMI	14 (20.0)	5 (7.8)	
	Stroke	1 (1.4)	4 (6.3)	
Family history	AMI	43 (61.4)	19 (29.7)	<0.001
	Stroke	5 (7.1)	6 (9.4)	
Influenza vaccination status [†]	Vaccinated	30 (42.9)	29 (45.3)	0.78

Table 1 Characteristics of study participants (n=134)

*28 cases (40%) and 25 controls (39%) with hypercholesterolaemia reported current statin use

[†]'Vaccinated' refers to receiving influenza vaccination in the current vaccination year (since September 2009).

Exposure variable	Prevalence – cases, n(%)	Prevalence – controls, n(%)	Unadjusted odds ratio (95% CI)	Adjusted odds ratio* (95% CI)
1. Respiratory illness	17 (24.3)	12 (18.8)	1.39 (0.60-3.19)	1.39 (0.56-3.47)
2. Influenza-like illness	10 (14.3)	3 (4.7)	3.39 (0.89-12.92)	3.17 (0.61-16.47)
3. Fever	11 (15.7)	4 (6.3)	2.80 (0.84-9.28)	2.42 (0.54-10.98)
4. Cough	21 (30.0)	10 (15.6)	2.31 (0.99-5.40)	2.04 (0.76-5.47)
5. Sore throat	10 (14.3)	8 (12.5)	1.17 (0.43-3.17)	1.43 (0.44-4.69)
6. Muscle ache	8 (11.4)	5 (7.8)	1.52 (0.47-4.92)	2.29 (0.59-8.92)
7. Influenza A IgA antibodies [‡]	25 (46.3)	28 (54.9)	0.71 (0.33-1.53)	0.82 (0.34-2.00)

Table 2 Odds ratios for the association between acute myocardial infarction and various respiratory illness exposure variables, unadjusted and adjusted

* Adjustments were made for age-group, gender, month of admission and influenza vaccination status (all exposures), family history of myocardial infarction (exposures 2, 3, 4 & 5) and personal history of myocardial infarction (exposures 2, 3, 4 & 5)

[‡]Note that n=105 (54 cases and 51 controls) for influenza antibodies where 8 equivocal results were excluded, compared to n=134 (70 cases and 64 controls) for all other exposures.

1
2
3 **Title** Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza

4
5 A H1N1 pandemic in London: a case control study

6
7
8
9 **Authors** Charlotte Warren-Gash¹, Anna Maria Geretti², George Hamilton³, Roby D. Rakhit⁴, Liam
10
11 Smeeth⁵, Andrew C. Hayward¹

12
13
14 **Affiliations**

15
16
17 ¹Centre for Infectious Disease Epidemiology, Research Department of Infection & Population Health,
18
19 UCL, London, UK

20
21 ² Institute of Infection and Global Health, University of Liverpool, UK

22
23 ³ Department of Vascular Surgery, Royal Free London Foundation Trust, London, UK

24
25 ⁴ Department of Cardiology, Royal Free London Foundation Trust, London, UK

26
27 ⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical
28
29 Medicine, London, UK

30
31
32
33
34
35 **Corresponding author**

36
37 Dr Charlotte Warren-Gash

38
39 Research Department of Infection & Population Health

40
41
42 1st Floor, Royal Free Hospital

43
44 Rowland Hill Street

45
46 London NW3 2PF

47
48 Email: c.warren-gash@ucl.ac.uk / charlotte.warren-gash@doctors.org.uk

49
50
51
52
53 Tel: 020 7794 0500 x36720 Fax: 020 7794 1224

54
55
56 **Word Count** Abstract 296, main text 2389 (excluding article summary, tables, figures, legends and refs)

ABSTRACT

Objective: To investigate recent respiratory and influenza-like illnesses in acute myocardial infarction patients compared to patients hospitalised for acute non vascular surgical conditions during the second wave of the 2009 influenza A H1N1 pandemic

Design: Case control study

Setting: Coronary care unit, acute cardiology and acute surgical admissions wards in a major teaching hospital in London, UK

Participants: 134 participants (70 cases and 64 controls) aged ≥ 40 years hospitalised for acute myocardial infarction and acute surgical conditions between 21/09/2009 and 28/02/2010, frequency-matched for gender, 5-year age-band and admission week

Primary exposure: Influenza-like illness (ILI - defined as feeling feverish with either cough or sore throat) within the last month. **Secondary exposures:** Acute respiratory illness within the last month not meeting ILI criteria; nasopharyngeal and throat swab positive for influenza virus

Results: 29 participants of 134 (21.6%) reported respiratory illness within the last month, of whom 13 (9.7%) had illnesses meeting ILI criteria. The most frequently reported category for timing of respiratory symptom onset was 8-14 days before admission (31.0% of illnesses). Cases were more likely than controls to report ILI – adjusted OR 3.17 (95% confidence interval 0.61-16.47) – as well as other key respiratory symptoms, and were less likely to have received influenza vaccination – adjusted OR 0.46 (95% CI, 0.19-1.12) – although differences were not statistically significant. No swabs were positive for influenza virus.

Conclusions: Point estimates suggested that recent ILI was more common in patients hospitalised with acute myocardial infarction than with acute surgical conditions during the second wave of the influenza A H1N1 pandemic, and influenza vaccination was associated with cardio-protection, although findings were not statistically significant. The study was underpowered, partly because the age groups typically

1
2
3 affected by acute myocardial infarction had low rates of infection with the pandemic influenza strain
4
5 compared to seasonal influenza.
6
7
8
9

10 **ARTICLE SUMMARY**

11 **Article focus**

- 12 • Seasonal influenza can trigger cardiovascular complications but the cardiac effects of the 2009
13 influenza pandemic are less clear.
- 14 • We aimed to investigate recent influenza-like illness in patients hospitalised with acute
15 myocardial infarction and surgical conditions during the 2009 influenza pandemic in London.
16
17
18
19
20
21
22
23

24 **Key messages**

- 25 • 14.3% of patients hospitalised with acute myocardial infarction (cases) reported recent
26 influenza-like illness compared to 4.7% of patients hospitalised for acute surgical conditions
27 (controls)
28
- 29 • Cases were more likely than controls to report a range of recent respiratory symptoms and less
30 likely to have received influenza vaccination though differences were not statistically significant
31
32
- 33 • The median age of cases with acute myocardial infarction was 63.6 years, whereas the majority
34 of people infected with pandemic influenza strain nationally were young
35
36
37
38
39
40
41
42

43 **Strengths and limitations**

- 44 • The study was underpowered to detect an effect, partly due to low infection rates with the
45 pandemic influenza virus in age-groups typically affected by acute myocardial infarction, but it
46 will inform design of future similar studies
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Seasonal influenza can trigger cardiovascular complications and deaths in vulnerable populations, especially the elderly and those with underlying medical conditions¹. Evidence to support the hypothesis that seasonal influenza may trigger acute myocardial infarction comes from a range of observational studies incorporating the effects of different circulating influenza strains and subtypes². In a pandemic situation, however, when there is global spread of a novel influenza strain, clinical and demographic profiles of those affected may change dramatically.

The most recent influenza pandemic was caused by an influenza A H1N1 strain (H1N1pdm09) that emerged in Mexico and the United States in April 2009^{3,4}. The UK experienced several waves of infection with this novel strain - a first wave occurred in spring and summer 2009 followed by a second wave in the winter of 2009/10 and a post-pandemic wave in winter 2010/11⁵. Initial evidence from the first wave in the UK suggested that typical illnesses were mild and affected mainly children and young people⁶. The average age of cases increased over subsequent waves of the pandemic⁷ but it is unclear how this affected clinical illness profiles. Vaccination coverage did not reach high levels until the post-pandemic season.

There have been reports of myocarditis, myocardial injury and left ventricular systolic dysfunction, **which may be reversible**, in patients with severe H1N1pdm09^{8,9}. It has been suggested that H1N1pdm09 was associated with higher rates of extra-pulmonary complications than seasonal influenza¹⁰ but this is difficult to compare as surveillance of severe influenza-related disease was greatly enhanced during the pandemic. A recent mathematical modelling study estimated that globally there were 83,300 cardiovascular deaths associated with the first twelve months of H1N1pdm09 circulation in adults aged >17 years¹¹, but the contribution of myocardial infarction deaths to this figure is unknown.

1
2
3 In this study we aimed to investigate whether patients hospitalised for acute myocardial infarction
4 during the winter wave of the influenza A H1N1 pandemic were more likely than surgical patients to
5 have experienced recent influenza-like illness or acute respiratory illness, or to have concurrent PCR
6 positive influenza or evidence of influenza A IgA antibodies in sera.
7
8
9
10
11
12

13 METHODS

14 Setting, design and participants

15
16
17 This was an observational case control study carried out in hospital in-patients at the Royal Free London
18 NHS Foundation Trust between 21st September 2009 and 28th February 2010. Cases were patients aged
19 ≥40 years who had experienced an acute myocardial infarction (defined as a rise in troponin T with
20 ischaemic symptoms and/or typical ECG changes, or by angiographic evidence of acute coronary artery
21 thrombosis during primary percutaneous coronary intervention). Controls were patients aged ≥40 years
22 admitted with an acute surgical condition such as appendicitis, bowel or urinary obstruction and no
23 history of myocardial infarction within the past month. These patients were chosen as controls because
24 their admissions were considered unlikely to be influenced by recent influenza-like illness. Cases and
25 controls were frequency matched for gender, age-group in 5 year age-bands and week of admission. All
26 were English-speaking and able to provide written informed consent. The study size was based on
27 numbers of eligible patients hospitalised during the influenza circulation period.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Exposures

47
48 The main exposure was recent influenza-like illness, defined as a history of feeling feverish with either
49 cough or sore throat within the last month. We also used the exposure recent acute respiratory
50 infection to capture a history of respiratory illness within the last month with any of the following
51 symptoms – fever, chills, dry cough, productive cough, myalgia, rhinorrhoea, blocked nose, sore throat,
52
53
54
55
56
57
58
59
60

1
2
3 wheeze, earache and fatigue – that did not meet criteria for influenza-like illness. Additional exposures
4
5 were nasopharyngeal and throat swabs testing positive for influenza by real-time polymerase chain
6
7 reaction (PCR), presence of IgA antibodies to influenza A in serum samples and self-reported influenza
8
9 vaccination status.
10

11 12 13 **Data sources and measurement**

14
15
16 We used a questionnaire to investigate recent respiratory and influenza-like illness as well as to capture
17
18 data on demographics, medical history and influenza vaccination status. Information on influenza
19
20 vaccination status was collected as 'vaccinated this year (from September 2009)', 'vaccinated last year
21
22 (September 2008 - August 2009)', 'vaccinated 2-5 years ago', 'vaccinated >5 years ago' and 'never
23
24 vaccinated'. Vaccination status was then re-categorised as a binary variable comprising 'vaccinated this
25
26 year' and 'unvaccinated', which included all other categories, to recognise that vaccinations in previous
27
28 seasons would not protect against the new circulating pandemic influenza strain. Medical records were
29
30 reviewed for details of the current admission and to confirm data on potential confounding factors.
31
32 Combined nasopharyngeal and throat swabs were taken from each participant, placed in viral transport
33
34 medium and transported to the laboratory for storage at -80°C. Samples were tested for the presence of
35
36 influenza virus RNA using a validated in house real-time PCR with a lower limit of detection of 1 RNA
37
38 copy per reaction, as previously described¹². A single serum sample was taken for quantification of IgA
39
40 antibodies to influenza A as a marker of recent exposure (as IgA levels peak at around 2 weeks after
41
42 exposure and reach baseline by around 4-6 weeks). Serum samples were centrifuged, frozen at -80°C
43
44 and batch tested using a commercially available enzyme-linked immunosorbent assay (EIA) for influenza
45
46 A IgA (Biosupply UK, cat no. RE56501). Antibody concentrations were initially explored as a continuous
47
48 variable, then categorised into 'positive' (>12 U/ml), 'equivocal' (8-12 U/ml) and 'negative' (>8 U/ml)
49
50 categories based on standard laboratory thresholds. Equivocal results were dropped for analyses.
51
52
53
54
55
56
57
58
59
60

Statistical methods

All analyses were carried out using Stata (*Stata Statistical Software: Release 12. College Station, TX: StataCorp LP*). Baseline comparability between cases and controls was assessed with X^2 tests.

Characteristics of participants with and without missing data were also compared using X^2 tests to assess any risk of bias associated with missing data. We used multivariable logistic regression analysis to investigate associations between recent influenza-like illness or acute respiratory illness exposures and case/ control status, controlling for the frequency-matching factors age-group, gender and month of admission and influenza vaccination status as an a priori confounder (all models) as well as for other potential confounding factors. An additional multivariable model in which influenza vaccination status was the main exposure was generated using the same approach. Potential confounders were examined using a backwards stepwise approach whereby factors independently associated with both exposure and outcome were included in models and likelihood ratio tests used to assess the effect of removing each one sequentially. If p values from likelihood ratio tests were <0.1 then factors were retained in the model.

RESULTS

Characteristics of study participants

134 participants were recruited, who comprised 70 cases from 106 approached (acceptance rate 66%) and 64 controls from 95 approached (acceptance rate 67%). Reasons for non-participation included lack of time, unwillingness to experience additional procedures and feeling tired or unwell. The median age of participants was 63.6 years (IQR 53.3-72.6) and 21% were female. Cases were more likely to be of Asian or Asian British ethnicity ($p=0.016$), to have a previous history of myocardial infarction ($p=0.04$) or a family history of myocardial infarction ($p<0.001$) than controls. Of the 70 patients hospitalised for acute myocardial infarction, 48 (68.5%) met criteria for ST-elevation myocardial infarction, 17 (24.3%)

1
2
3 had a non ST-elevation myocardial infarction and in 5 (7.1%) cases the subtype of myocardial infarction
4
5 was unspecified. Control patients were admitted with a range of acute non-vascular surgical
6
7 presentations that included colorectal, urological and orthopaedic conditions.
8
9

10
11 **Table 1**

12
13
14 **Timing of participants' admissions in relation to national influenza circulation**

15
16
17 A comparison of study participants' dates of admission with national rates of GP consultations for
18
19 influenza-like illness (ILI) based on RCGP surveillance data is shown in figure 1. The peak week for ILI
20
21 consultations in England was week 43 (ending 25th October 2009) when the rate was 42.8 per 100,000.
22
23 This was also the peak week for influenza virus circulation according to data from virological sentinel
24
25 surveillance schemes, when the proportion of positive samples reached 41.2%. Our recruitment period
26
27 spanned this period of peak influenza circulation.
28
29

30
31
32 **Figure 1**

33
34 **Recent respiratory and influenza-like illness**

35
36
37 17 cases (24.3%) and 12 controls (18.8%) reported respiratory illness in the month preceding hospital
38
39 admission. 13 illnesses – reported by 10 cases (14.3%) and 3 controls (4.7%) – met criteria for influenza-
40
41 like illness (defined as feeling feverish with cough and/or sore throat). The most frequently reported
42
43 category for the timing of respiratory symptom onset was 8-14 days before admission (31.0% of
44
45 illnesses). 4-7 days was the most frequently reported category for length of illness (37.9% of illnesses).
46
47 Symptom profiles of participants reporting recent respiratory illness are shown in figure 2. No swabs
48
49 tested positive for influenza virus nucleic acid. Serum samples were available on 113 of 134 participants
50
51 (84.3%). There were no significant differences in characteristics of participants with and without missing
52
53 serum samples (data not shown). 25 cases (43.1%) and 28 controls (50.9%) tested positive for serum
54
55
56
57
58
59
60

1
2
3 influenza A IgA antibodies. 62% of participants who were seropositive had received influenza
4
5 vaccination during the study period compared to 31% of seronegative participants. Overall 44.0% of
6
7 participants were vaccinated. The proportion of participants recruited in each month who were
8
9 vaccinated increased from 0% in September 2009, to 29.6% in October 2009, 44.8% in November 2009,
10
11 55.0% in December 2009, 72.0% in January 2010 and was 50% in February 2010.
12
13

14 15 16 Figure 2

17
18 Cases were more likely to have reported influenza-like illness than controls – adjusted OR 3.17 (95%
19
20 confidence interval 0.61-16.47) – as well as other key respiratory illness symptoms, although differences
21
22 were not statistically significant. Results from this logistic regression analysis are summarised in table 2.
23
24 There was also a trend towards a protective effect of influenza vaccination against myocardial infarction
25
26 – adjusted OR 0.46 (95% CI, 0.19-1.12) – after controlling for age-group, gender, month of admission and
27
28 personal history of AMI.
29
30
31
32

33 34 35 Table 2

36 37 38 DISCUSSION

39
40 The study was supportive of the hypothesis that recent respiratory and in particular influenza-like
41
42 illnesses occurring during the second wave of the influenza A H1N1 pandemic were more common in
43
44 patients hospitalised with acute myocardial infarction than with acute surgical conditions. Influenza
45
46 vaccination was also associated with protection against myocardial infarction, although differences were
47
48 not statistically significant. While we had hypothesised that more adults would be infected during the
49
50 second pandemic wave due to the expected upwards shift in age distribution of infections, national
51
52 rates of influenza-like illness remained low⁵, especially in age groups typically affected by acute
53
54 myocardial infarction. The study was therefore underpowered to detect an effect, partly due to limited
55
56 numbers of infections among participants.
57
58
59
60

1
2
3
4
5
6
7 Using self-reported recent respiratory and influenza-like illness as exposures introduced the possibility
8
9 of reporting or recall bias. Nonetheless this method allows greater sensitivity to detect recent
10
11 respiratory symptoms than relying on reports of medically attended illnesses, which comprise only a
12
13 small minority of influenza cases¹³. As cases and controls were frequency matched on week of
14
15 admission, external factors such as media coverage of the influenza pandemic should not have had a
16
17 differential effect on respiratory illness reporting. We chose to test both nasopharyngeal and throat
18
19 swabs to increase the sensitivity of virus detection. It was perhaps unsurprising, however, that none of
20
21 the nasopharyngeal and throat swabs was positive for influenza virus given a) the low rates of infection
22
23 in this age-group⁵ and b) that the majority of viral shedding in influenza occurs in the first 2-3 days after
24
25 symptom onset¹⁴ whereas most reported respiratory symptoms in study participants occurred 8-14 days
26
27 before admission. Based on our findings it seems unlikely that any delayed cardiac effect of influenza is
28
29 linked to ongoing or prolonged virus replication or shedding in the respiratory tract. Influenza serology
30
31 is difficult to interpret in vaccinated participants as it not possible to distinguish antibody rises caused by
32
33 infection from those caused by vaccination. Validation of the IgA assay used suggests it has acceptable
34
35 sensitivity and specificity to detect recent seasonal influenza A infection¹⁵ but its effect with the
36
37 pandemic strain H1N1pdm09 is unclear. It has previously been noted that serological studies carried out
38
39 during the 2009 influenza pandemic were severely hampered by cross reactivity both with vaccine and
40
41 with seasonal influenza strains⁷.

42
43
44
45
46
47
48
49
50 Previous observational studies using large electronic primary care databases have found an association
51
52 between GP consultation for acute respiratory infection in the last month and risk of acute myocardial
53
54 infarction¹⁶⁻¹⁸. Although studies were conducted over different time periods, they encompassed the
55
56 effect of varying seasonal influenza strains. Our recent self-controlled case series study using linked
57
58
59
60

1
2
3 primary care and cardiac disease registry data from 3,927 patients also included acute respiratory
4
5 infection consultations occurring during the first wave of H1N1pdm09 circulation¹⁹. We found an
6
7 incidence ratio for acute myocardial infarction of 4.19 (95% confidence interval 3.18-5.53) in the first 1-3
8
9 days after acute respiratory infection, with the risk falling to baseline after 28 days¹⁹. Elderly people and
10
11 those consulting for an infection judged most likely to be due to influenza were at greatest risk. During
12
13 the 2009 influenza pandemic people with underlying cardiovascular disease were much more likely to
14
15 be hospitalised¹³ and to die²⁰ from a range of causes attributable to pandemic influenza. Although most
16
17 deaths from H1N1pdm09 occurred in younger people, this was partly a function of the age distribution
18
19 of infections: in the UK the case fatality rate in the elderly was much higher than in younger age-groups⁵
20
21 but overall numbers of deaths were small as few elderly people were infected.
22
23
24
25
26
27

28
29 Various biological mechanisms are proposed to underlie a relationship between influenza or acute
30
31 respiratory infection and myocardial infarction²¹. Acute respiratory infections may result in a host of
32
33 acute inflammatory and haemostatic effects leading to systemic inflammation, altered plasma viscosity,
34
35 coagulability and haemodynamic changes²² as well as promoting local endothelial dysfunction, coronary
36
37 inflammation and plaque rupture²³. Immobility associated with bed-rest and dehydration might
38
39 potentiate these processes.
40
41
42
43
44

45
46 In conclusion, this study suggests that recent ILI occurring during the 2009 influenza pandemic was more
47
48 common in AMI patients. Taken in the context of previous work, this helps to support the hypothesis
49
50 that, as with other influenza strains, H1N1pdm09 could potentially trigger AMI in vulnerable groups. It
51
52 is likely, however, that the effect is not specific to influenza and could have also been due to other
53
54 viruses circulating at the time. The population impact of H1N1pdm09 on rates of hospitalisations and
55
56 deaths from myocardial infarction is also likely to have been relatively low given the mismatch between
57
58
59
60

1
2
3 the ages of those typically affected by H1N1pdm09 and acute coronary events as well as the relatively
4
5 mild clinical effects of this influenza strain.
6
7
8
9

10 **Acknowledgments**

11
12
13 We thank all patients who agreed to participate in this study and nurses on the cardiology and surgical
14
15 wards at the Royal Free Hospital who helped to identify potential participants. We acknowledge Mauli
16
17 Patel at the Royal Free Virology Laboratory who kindly processed, stored and tested samples.
18
19

20 **Contributors**

21
22
23 CWG conceived and designed the study, recruited participants, collected and analysed data and wrote
24
25 the manuscript. AMG, GH, RDR, LS and ACH assisted with study design. AMG provided laboratory
26
27 resources. CWG, AMG, RDR, LS and ACH interpreted results. AMG, GH, RDR, LS and ACH critically
28
29 revised the manuscript for intellectual content. LS and ACH provided supervision. All authors approved
30
31 the final version of the manuscript.
32
33
34
35

36 **Funding statement**

37
38
39 This work was funded by a Medical Research Council Clinical Research Training Fellowship for CWG,
40
41 grant number G0800689. LS is supported by a Wellcome Trust Senior Research Fellowship in Clinical
42
43 Science, grant number 098504/Z/12/Z.
44
45
46

47 **Competing interests statement**

48
49
50 None declared
51
52

53 **Data sharing statement**

54
55
56 No additional data are available
57
58
59
60

References

1. Cox NJ, Subbarao K (1999) Influenza. *The Lancet* 354: 1277–1282.
2. Warren-Gash C, Smeeth L, Hayward AC (2009) Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. *The Lancet Infectious Diseases* 9: 601–610.
3. Swine influenza A (H1N1) infection in two children – Southern California, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 400–402.
4. Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 467–470.
5. Health Protection Agency (2010) Epidemiological report of pandemic (H1N1) 2009 in the United Kingdom: April 2009 - May 2010.
6. McLean E, Pebody RG, Campbell C, Chamberland M, Hawkins C, et al. (2010) Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol Infect* 138: 1531–1541.
7. Lagacé-Wiens PRS, Rubinstein E, Gumel A (2010) Influenza epidemiology – past, present, and future. *Crit Care Med* 38: e1–e9.
8. Chacko B, Peter JV, Pichamuthu K, Ramakrishna K, Moorthy M, et al. (2012) Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. *J Crit Care* 27: 106.e1–6.
9. Martin SS, Hollingsworth CL, Norfolk SG, Wolfe CR, Hollingsworth JW. (2010) Reversible cardiac dysfunction associated with pandemic 2009 influenza A (H1N1). *Chest* 137: 1195-7.
10. Lee N, Chan PKS, Lui GCY, Wong BCK, Sin WWY, et al. (2011) Complications and Outcomes of Pandemic 2009 Influenza A (H1N1) Virus Infection in Hospitalized Adults: How Do They Differ From Those in Seasonal Influenza? *J Infect Dis* 203: 1739–1747.
11. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, et al. (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *The Lancet Infectious Diseases* 12: 687–695.
12. Khanom AB, Velvin C, Hawrami K, Schutten M, Patel M, et al. (2011) Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care. *J Infect* 62: 52–58.
13. Campbell CNJ, Mytton OT, McLean EM, Rutter PD, Pebody RG, et al. (2010) Hospitalization in two waves of pandemic influenza A(H1N1) in England. *Epidemiology & Infection* 139: 1560–1569.
14. Lau LLH, Cowling BJ, Fang VJ, Chan K-H, Lau EHY, et al. (2010) Viral shedding and clinical illness in naturally acquired influenza virus infections. *J Infect Dis* 201: 1509–1516.
15. Rothbarth PH, Groen J, Bohnen AM, De Groot R, Osterhaus AD (1999) Influenza virus serology – a comparative study. *J Virol Methods* 78: 163–169.
16. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine* 351: 2611–2618.
17. Clayton TC, Thompson M, Meade TW (2008) Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. *Eur Heart J* 29: 96–103.
18. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H, et al. (1998) Acute respiratory-tract infections and risk of first-time acute myocardial infarction. *The Lancet* 351: 1467–1471.
19. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, et al. (2012) Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. *J Infect Dis* 206: 1652–1659.
20. Mytton OT, Rutter PD, Mak M, Stanton E, Sachedina N, et al. (2012) Mortality due to pandemic (H1N1) 2009 influenza in England: a comparison of the first and second waves. *Epidemiology & Infection* 140: 1533–1541.

- 1
- 2
- 3
- 4 21. Bazaz R, Marriott HM, Francis SE, Dockrell DH (2013) Mechanistic links between acute respiratory
- 5 tract infections and acute coronary syndromes. *J Infect* 66: 1-17.
- 6
- 7 22. Harskamp RE, Van Ginkel MW (2008) Acute respiratory tract infections: a potential trigger for the
- 8 acute coronary syndrome. *Annals of Medicine* 40: 121–128.
- 9
- 10 23. Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: does acute endothelial
- 11 dysfunction provide a link? *The Lancet* 349: 1391–1392.

12 **Figure legends**

13

14 **Figure 1** Number of study participants admitted by influenza surveillance week compared to weekly ILI

15 rates per 100,000 based on national RCGP surveillance data

16

17

18

19

20 **Figure 2** Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory

21 illness

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Characteristic	Category	Cases (n=70)	Controls (n=64)	P value
Age group	40-49	8 (11.4)	13 (20.3)	0.61
	50-59	19 (27.1)	18 (28.1)	
	60-69	19 (27.1)	15 (23.4)	
	70-79	17 (24.3)	11 (17.2)	
	80+	7 (10.0)	7 (10.9)	
Gender	Female	13 (18.6)	15 (23.4)	0.49
	Male	57 (81.4)	49 (76.6)	
Admission month	September	8 (11.4)	7 (10.9)	0.92
	October	12 (17.1)	15 (23.4)	
	November	15 (21.4)	14 (21.9)	
	December	10 (14.3)	10 (15.6)	
	January	14 (20.0)	11 (17.2)	
	February	11 (15.7)	7 (10.9)	
Ethnicity	Asian or Asian British	18 (25.7)	6 (9.4)	0.03
	Black or Black British	2 (2.9)	0 (0.0)	
	Mixed	0 (0.0)	1 (1.6)	
	White	50 (71.4)	57 (89.1)	
BMI category	18.5-24.9	20 (30.8)	23 (39.0)	0.41
	25.0-29.9	36 (55.4)	24 (40.7)	
	30.0-39.9	8 (12.3)	10 (17.0)	
	40.0-max	1 (1.5)	2 (3.4)	
Smoker	No never	22 (31.4)	23 (35.9)	0.77
	Yes current	27 (38.6)	21 (32.8)	
	Yes ex	21 (30.0)	20 (31.3)	
Past medical history	Hypercholesterolaemia*	34 (48.6)	28 (43.8)	0.58
	Diabetes	14 (20.0)	12 (18.8)	0.86
	Hypertension	37 (52.9)	26 (40.6)	0.16
	AMI	14 (20.0)	5 (7.8)	0.04
	Stroke	1 (1.4)	4 (6.3)	0.14
Family history	AMI	43 (61.4)	19 (29.7)	<0.001
	Stroke	5 (7.1)	6 (9.4)	0.64
Influenza vaccination status†	Vaccinated	30 (42.9)	29 (45.3)	0.78

Table 1 Characteristics of study participants (n=134)

*28 cases (40%) and 25 controls (39%) with hypercholesterolaemia reported current statin use

[†]'Vaccinated' refers to receiving influenza vaccination in the current vaccination year (since September 2009).


Exposure variable	Prevalence – cases, n(%)	Prevalence – controls, n(%)	Unadjusted odds ratio (95% CI)	Adjusted odds ratio* (95% CI)
1. Respiratory illness	17 (24.3)	12 (18.8)	1.39 (0.60-3.19)	1.39 (0.56-3.47)
2. Influenza-like illness	10 (14.3)	3 (4.7)	3.39 (0.89-12.92)	3.17 (0.61-16.47)
3. Fever	11 (15.7)	4 (6.3)	2.80 (0.84-9.28)	2.42 (0.54-10.98)
4. Cough	21 (30.0)	10 (15.6)	2.31 (0.99-5.40)	2.04 (0.76-5.47)
5. Sore throat	10 (14.3)	8 (12.5)	1.17 (0.43-3.17)	1.43 (0.44-4.69)
6. Muscle ache	8 (11.4)	5 (7.8)	1.52 (0.47-4.92)	2.29 (0.59-8.92)
7. Influenza A IgA antibodies [‡]	25 (46.3)	28 (54.9)	0.71 (0.33-1.53)	0.82 (0.34-2.00)

Table 2 Odds ratios for the association between acute myocardial infarction and various respiratory illness exposure variables, unadjusted and adjusted

* Adjustments were made for age-group, gender, month of admission and influenza vaccination status (all exposures), family history of myocardial infarction (exposures 2, 3, 4 & 5) and personal history of myocardial infarction (exposures 2, 3, 4 & 5)


[‡]Note that n=105 (54 cases and 51 controls) for influenza antibodies where 8 equivocal results were excluded, compared to n=134 (70 cases and 64 controls) for all other exposures.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Number of study participants admitted by influenza surveillance week compared to weekly ILI rates per 100,000 based on national RCGP surveillance data
 264x158mm (96 x 96 DPI)

review only



Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory illness
264x158mm (96 x 96 DPI)

Review only

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation	Reported on page no.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	5
		(b) For matched studies, give matching criteria and the number of controls per case	Frequency matching criteria given on p5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	Study size based on numbers of eligible patients hospitalised during the influenza circulation period
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how matching of cases and controls was addressed	N/A

		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	Data not systematically collected but reasons for non-participation include lack of time and feeling unwell during admission
		(c) Consider use of a flow diagram	Not done as no follow up with this study design. Fig 1 shows recruitment over time.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1 and p8
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza A H1N1 pandemic in London: a case control study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002604.R2
Article Type:	Research
Date Submitted by the Author:	27-Mar-2013
Complete List of Authors:	Warren-Gash, Charlotte; UCL, Research Department of Infection & Population Health Geretti, Anna Maria; University of Liverpool, Institute of Infection and Global Health Hamilton, George; Royal Free London Foundation Trust, Department of Vascular Surgery Rakhit, Roby; Royal Free London Foundation Trust, Department of Cardiology Smeeth, Liam; London School of Hygiene and Tropical Medicine, Epidemiology and Population Health Hayward, Andrew; University College London, Infection and Population Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Infectious diseases, Cardiovascular medicine
Keywords:	Myocardial infarction < CARDIOLOGY, Epidemiology < INFECTIOUS DISEASES, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

1
2
3 **Title** Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza
4
5 A H1N1 pandemic in London: a case control study
6
7

8
9 **Authors** Charlotte Warren-Gash¹, Anna Maria Geretti², George Hamilton³, Roby D. Rakhit⁴, Liam
10
11 Smeeth⁵, Andrew C. Hayward¹
12
13

14
15 **Affiliations**

16
17 ¹Centre for Infectious Disease Epidemiology, Research Department of Infection & Population Health,
18
19 UCL, London, UK
20
21

22 ² Institute of Infection and Global Health, University of Liverpool, UK
23

24 ³ Department of Vascular Surgery, Royal Free London Foundation Trust, London, UK
25

26 ⁴ Department of Cardiology, Royal Free London Foundation Trust, London, UK
27

28 ⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Medicine, London, UK

36 **Corresponding author**

37
38 Dr Charlotte Warren-Gash

39
40 Research Department of Infection & Population Health

41
42 1st Floor, Royal Free Hospital

43
44 Rowland Hill Street

45
46 London NW3 2PF

47
48 Email: c.warren-gash@ucl.ac.uk / charlotte.warren-gash@doctors.org.uk

49
50
51
52
53
54
55
56
57
58
59
60
Tel: 020 7794 0500 x36720 Fax: 020 7794 1224

Word Count Abstract 296, main text 2505 (excluding article summary, tables, figures, legends and refs)

ABSTRACT

Objective: To investigate recent respiratory and influenza-like illnesses in acute myocardial infarction patients compared to patients hospitalised for acute non vascular surgical conditions during the second wave of the 2009 influenza A H1N1 pandemic

Design: Case control study

Setting: Coronary care unit, acute cardiology and acute surgical admissions wards in a major teaching hospital in London, UK

Participants: 134 participants (70 cases and 64 controls) aged ≥ 40 years hospitalised for acute myocardial infarction and acute surgical conditions between 21/09/2009 and 28/02/2010, frequency-matched for gender, 5-year age-band and admission week

Primary exposure: Influenza-like illness (ILI - defined as feeling feverish with either cough or sore throat) within the last month. **Secondary exposures:** Acute respiratory illness within the last month not meeting ILI criteria; nasopharyngeal and throat swab positive for influenza virus

Results: 29 participants of 134 (21.6%) reported respiratory illness within the last month, of whom 13 (9.7%) had illnesses meeting ILI criteria. The most frequently reported category for timing of respiratory symptom onset was 8-14 days before admission (31.0% of illnesses). Cases were more likely than controls to report ILI – adjusted OR 3.17 (95% confidence interval 0.61-16.47) – as well as other key respiratory symptoms, and were less likely to have received influenza vaccination – adjusted OR 0.46 (95% CI, 0.19-1.12) – although differences were not statistically significant. No swabs were positive for influenza virus.

Conclusions: Point estimates suggested that recent ILI was more common in patients hospitalised with acute myocardial infarction than with acute surgical conditions during the second wave of the influenza A H1N1 pandemic, and influenza vaccination was associated with cardio-protection, although findings were not statistically significant. The study was underpowered, partly because the age groups typically

1
2
3 affected by acute myocardial infarction had low rates of infection with the pandemic influenza strain
4
5 compared to seasonal influenza.
6
7
8
9

10 **ARTICLE SUMMARY**

11 **Article focus**

- 12 • Seasonal influenza can trigger cardiovascular complications but the cardiac effects of the 2009
13 influenza pandemic are less clear.
- 14 • We aimed to investigate recent influenza-like illness in patients hospitalised with acute
15 myocardial infarction and surgical conditions during the 2009 influenza pandemic in London.
16
17
18
19
20
21
22
23

24 **Key messages**

- 25 • 14.3% of patients hospitalised with acute myocardial infarction (cases) reported recent
26 influenza-like illness compared to 4.7% of patients hospitalised for acute surgical conditions
27 (controls)
- 28 • Cases were more likely than controls to report a range of recent respiratory symptoms and less
29 likely to have received influenza vaccination though differences were not statistically significant
30
31
32
- 33 • The median age of cases with acute myocardial infarction was 63.6 years, whereas the majority
34 of people infected with pandemic influenza strain nationally were young
35
36
37
38
39
40
41
42

43 **Strengths and limitations**

- 44 • The study was underpowered to detect an effect, partly due to low infection rates with the
45 pandemic influenza virus in age-groups typically affected by acute myocardial infarction, but it
46 will inform design of future similar studies
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Seasonal influenza can trigger cardiovascular complications and deaths in vulnerable populations, especially the elderly and those with underlying medical conditions¹. Evidence to support the hypothesis that seasonal influenza may trigger acute myocardial infarction comes from a range of observational studies incorporating the effects of different circulating influenza strains and subtypes². In a pandemic situation, however, when there is global spread of a novel influenza strain, clinical and demographic profiles of those affected may change dramatically.

The most recent influenza pandemic was caused by an influenza A H1N1 strain (H1N1pdm09) that emerged in Mexico and the United States in April 2009^{3,4}. The UK experienced several waves of infection with this novel strain - a first wave occurred in spring and summer 2009 followed by a second wave in the winter of 2009/10 and a post-pandemic wave in winter 2010/11⁵. Initial evidence from the first wave in the UK suggested that typical illnesses were mild and affected mainly children and young people⁶. The average age of cases increased over subsequent waves of the pandemic⁷ but it is unclear how this affected clinical illness profiles. Vaccination coverage did not reach high levels until the post-pandemic season.

There have been reports of myocarditis, myocardial injury and left ventricular systolic dysfunction, which may be reversible, in patients with severe H1N1pdm09^{8,9}. It has been suggested that H1N1pdm09 was associated with higher rates of extra-pulmonary complications than seasonal influenza¹⁰ but this is difficult to compare as surveillance of severe influenza-related disease was greatly enhanced during the pandemic. A recent mathematical modelling study estimated that globally there were 83,300 cardiovascular deaths associated with the first twelve months of H1N1pdm09 circulation in adults aged >17 years¹¹, but the contribution of myocardial infarction deaths to this figure is unknown.

1
2
3 In this study we aimed to investigate whether patients hospitalised for acute myocardial infarction
4 during the winter wave of the influenza A H1N1 pandemic were more likely than surgical patients to
5 have experienced recent influenza-like illness or acute respiratory illness, or to have concurrent PCR
6 positive influenza or evidence of influenza A IgA antibodies in sera.
7
8
9
10
11
12

13 **METHODS**

14 **Setting, design and participants**

15
16
17
18
19
20 This was an observational case control study carried out in hospital in-patients at the Royal Free London
21 NHS Foundation Trust between 21st September 2009 and 28th February 2010. Cases were patients aged
22 ≥40 years who had experienced an acute myocardial infarction (defined as a rise in troponin T with
23 ischaemic symptoms and/or typical ECG changes, or by angiographic evidence of acute coronary artery
24 thrombosis during primary percutaneous coronary intervention). Controls were patients aged ≥40 years
25 admitted with an acute surgical condition such as appendicitis, bowel or urinary obstruction and no
26 history of myocardial infarction within the past month. These patients were chosen as controls because
27 their admissions were considered unlikely to be influenced by recent influenza-like illness. Cases and
28 controls were frequency matched for gender, age-group in 5 year age-bands and week of admission. All
29 were English-speaking and able to provide written informed consent. The study size was based on
30 numbers of eligible patients hospitalised during the influenza circulation period.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Exposures**

47
48
49 The main exposure was recent influenza-like illness, defined as a history of feeling feverish with either
50 cough or sore throat within the last month. We also used the exposure recent acute respiratory
51 infection to capture a history of respiratory illness within the last month with any of the following
52 symptoms – fever, chills, dry cough, productive cough, myalgia, rhinorrhoea, blocked nose, sore throat,
53
54
55
56
57
58
59
60

1
2
3 wheeze, earache and fatigue – that did not meet criteria for influenza-like illness. Additional exposures
4
5 were nasopharyngeal and throat swabs testing positive for influenza by real-time polymerase chain
6
7 reaction (PCR), presence of IgA antibodies to influenza A in serum samples and self-reported influenza
8
9 vaccination status.
10

11 12 13 **Data sources and measurement**

14
15
16 We used a questionnaire to investigate recent respiratory and influenza-like illness as well as to capture
17
18 data on demographics, medical history and influenza vaccination status. Information on influenza
19
20 vaccination status was collected as ‘vaccinated this year (from September 2009)’, ‘vaccinated last year
21
22 (September 2008 - August 2009)’, ‘vaccinated 2-5 years ago’, ‘vaccinated >5 years ago’ and ‘never
23
24 vaccinated’. Vaccination status was then re-categorised as a binary variable comprising ‘vaccinated this
25
26 year’ and ‘unvaccinated’, which included all other categories, to recognise that vaccinations in previous
27
28 seasons would not protect against the new circulating pandemic influenza strain. Medical records were
29
30 reviewed for details of the current admission and to confirm data on potential confounding factors.
31
32 Combined nasopharyngeal and throat swabs were taken from each participant, placed in viral transport
33
34 medium and transported to the laboratory for storage at -80°C. Samples were tested for the presence of
35
36 influenza virus RNA using a validated in house real-time PCR with a lower limit of detection of 1 RNA
37
38 copy per reaction, as previously described¹². A single serum sample was taken for quantification of IgA
39
40 antibodies to influenza A as a marker of recent exposure (as IgA levels peak at around 2 weeks after
41
42 exposure and reach baseline by around 4-6 weeks). Serum samples were centrifuged, frozen at -80°C
43
44 and batch tested using a commercially available enzyme-linked immunosorbent assay (EIA) for influenza
45
46 A IgA (Biosupply UK, cat no. RE56501). Antibody concentrations were initially explored as a continuous
47
48 variable, then categorised into ‘positive’ (>12 U/ml), ‘equivocal’ (8-12 U/ml) and ‘negative’ (>8 U/ml)
49
50 categories based on standard laboratory thresholds. Equivocal results were dropped for analyses.
51
52
53
54
55
56
57
58
59
60

Statistical methods

All analyses were carried out using Stata (*Stata Statistical Software: Release 12. College Station, TX: StataCorp LP*). Baseline comparability between cases and controls was assessed with χ^2 tests.

Characteristics of participants with and without missing data were also compared using χ^2 tests to assess any risk of bias associated with missing data. We used multivariable logistic regression analysis to investigate associations between recent influenza-like illness or acute respiratory illness exposures and case/ control status, controlling for the frequency-matching factors age-group, gender and month of admission and influenza vaccination status as an a priori confounder (all models) as well as for other potential confounding factors. An additional multivariable model in which influenza vaccination status was the main exposure was generated using the same approach. Potential confounders were examined using a backwards stepwise approach whereby factors independently associated with both exposure and outcome were included in models and likelihood ratio tests used to assess the effect of removing each one sequentially. If p values from likelihood ratio tests were <0.1 then factors were retained in the model.

RESULTS

Characteristics of study participants

134 participants were recruited, who comprised 70 cases from 106 approached (acceptance rate 66%) and 64 controls from 95 approached (acceptance rate 67%). Reasons for non-participation included lack of time, unwillingness to experience additional procedures and feeling tired or unwell. The median age of participants was 63.6 years (IQR 53.3-72.6) and 21% were female. Cases were more likely to be of Asian or Asian British ethnicity ($p=0.016$), to have a previous history of myocardial infarction ($p=0.04$) or a family history of myocardial infarction ($p<0.001$) than controls. Of the 70 patients hospitalised for acute myocardial infarction, 48 (68.5%) met criteria for ST-elevation myocardial infarction, 17 (24.3%)

1
2
3 had a non ST-elevation myocardial infarction and in 5 (7.1%) cases the subtype of myocardial infarction
4
5 was unspecified. Control patients were admitted with a range of acute non-vascular surgical
6
7 presentations that included colorectal, urological and orthopaedic conditions.
8
9

10
11 **Table 1**

12
13
14 **Timing of participants' admissions in relation to national influenza circulation**

15
16
17 A comparison of study participants' dates of admission with national rates of GP consultations for
18
19 influenza-like illness (ILI) based on RCGP surveillance data is shown in figure 1. The peak week for ILI
20
21 consultations in England was week 43 (ending 25th October 2009) when the rate was 42.8 per 100,000.
22
23 This was also the peak week for influenza virus circulation according to data from virological sentinel
24
25 surveillance schemes, when the proportion of positive samples reached 41.2%. Our recruitment period
26
27 spanned this period of peak influenza circulation.
28
29

30
31
32 **Figure 1**

33
34 **Recent respiratory and influenza-like illness**

35
36
37 17 cases (24.3%) and 12 controls (18.8%) reported respiratory illness in the month preceding hospital
38
39 admission. 13 illnesses – reported by 10 cases (14.3%) and 3 controls (4.7%) – met criteria for influenza-
40
41 like illness (defined as feeling feverish with cough and/or sore throat). The most frequently reported
42
43 category for the timing of respiratory symptom onset was 8-14 days before admission (31.0% of
44
45 illnesses). 4-7 days was the most frequently reported category for length of illness (37.9% of illnesses).
46
47 Symptom profiles of participants reporting recent respiratory illness are shown in figure 2. No swabs
48
49 tested positive for influenza virus nucleic acid. Serum samples were available on 113 of 134 participants
50
51 (84.3%). There were no significant differences in characteristics of participants with and without missing
52
53 serum samples (data not shown). 25 cases (43.1%) and 28 controls (50.9%) tested positive for serum
54
55
56
57
58
59
60

1
2
3 influenza A IgA antibodies. 62% of participants who were seropositive had received influenza
4
5 vaccination during the study period compared to 31% of seronegative participants. Overall 44.0% of
6
7 participants were vaccinated. The proportion of participants recruited in each month who were
8
9 vaccinated increased from 0% in September 2009, to 29.6% in October 2009, 44.8% in November 2009,
10
11 55.0% in December 2009, 72.0% in January 2010 and was 50% in February 2010.
12
13

14 15 16 **Figure 2**

17
18 Cases were more likely to have reported influenza-like illness than controls – adjusted OR 3.17 (95%
19
20 confidence interval 0.61-16.47) – as well as other key respiratory illness symptoms, although differences
21
22 were not statistically significant. Results from this logistic regression analysis are summarised in table 2.
23
24 There was also a trend towards a protective effect of influenza vaccination against myocardial infarction
25
26 – adjusted OR 0.46 (95% CI, 0.19-1.12) – after controlling for age-group, gender, month of admission and
27
28 personal history of AMI.
29
30
31
32

33 **Table 2**

34 35 36 **DISCUSSION**

37
38
39 The study was supportive of the hypothesis that recent respiratory and in particular influenza-like
40
41 illnesses occurring during the second wave of the influenza A H1N1 pandemic were more common in
42
43 patients hospitalised with acute myocardial infarction than with acute surgical conditions. Influenza
44
45 vaccination was also associated with protection against myocardial infarction, although differences were
46
47 not statistically significant. While we had hypothesised that more adults would be infected during the
48
49 second pandemic wave due to the expected upwards shift in age distribution of infections, national
50
51 rates of influenza-like illness remained low⁵, especially in age groups typically affected by acute
52
53 myocardial infarction. The study was therefore underpowered to detect an effect, partly due to limited
54
55 numbers of infections among participants.
56
57
58
59
60

1
2
3
4
5
6
7 Using self-reported recent respiratory and influenza-like illness as exposures introduced the possibility
8
9 of reporting or recall bias. Nonetheless this method allows greater sensitivity to detect recent
10
11 respiratory symptoms than relying on reports of medically attended illnesses, which comprise only a
12
13 small minority of influenza cases¹³. As cases and controls were frequency matched on week of
14
15 admission, external factors such as media coverage of the influenza pandemic should not have had a
16
17 differential effect on respiratory illness reporting. We chose to test both nasopharyngeal and throat
18
19 swabs to increase the sensitivity of virus detection. It was perhaps unsurprising, however, that none of
20
21 the nasopharyngeal and throat swabs was positive for influenza virus given a) the low rates of infection
22
23 in this age-group⁵ and b) that the majority of viral shedding in influenza occurs in the first 2-3 days after
24
25 symptom onset¹⁴ whereas most reported respiratory symptoms in study participants occurred 8-14 days
26
27 before admission. Based on our findings it seems unlikely that any delayed cardiac effect of influenza is
28
29 linked to ongoing or prolonged virus replication or shedding in the respiratory tract. Influenza serology
30
31 is difficult to interpret in vaccinated participants as it not possible to distinguish antibody rises caused by
32
33 infection from those caused by vaccination. Validation of the IgA assay used suggests it has acceptable
34
35 sensitivity and specificity to detect recent seasonal influenza A infection¹⁵ but its effect with the
36
37 pandemic strain H1N1pdm09 is unclear. It has previously been noted that serological studies carried out
38
39 during the 2009 influenza pandemic were severely hampered by cross reactivity both with vaccine and
40
41 with seasonal influenza strains⁷.

42
43
44
45
46
47
48
49
50 Previous observational studies using large electronic primary care databases have found an association
51
52 between GP consultation for acute respiratory infection in the last month and risk of acute myocardial
53
54 infarction¹⁶⁻¹⁸. Although studies were conducted over different time periods, they encompassed the
55
56 effect of varying seasonal influenza strains. In the present study, we controlled for important potential
57
58
59
60

1
2
3 confounders such as influenza vaccination status, and showed that statin use was equally prevalent in
4 cases and controls. We did not, however, have complete data on other drugs that have been
5
6 hypothesised to have immune-regulatory effects (such as ACE inhibitors ,angiotensin receptor blockers
7
8 (ARBs), metformin, glitazones and fibrates). If these agents reduce the likelihood of people experiencing
9
10 ILI and were more commonly used in cases than controls they could potentially have confounded the
11
12 relationship between ILI and AMI. It was reassuring, however, that our results were consistent with
13
14 those obtained in our recent self-controlled case series study - a design that implicitly controls for fixed
15
16 confounders. In this study we used linked primary care and cardiac disease registry records from 3,927
17
18 patients from 2003-2009, which also included acute respiratory infection consultations occurring during
19
20 the first wave of H1N1pdm09 circulation¹⁹. We found an incidence ratio for acute myocardial infarction
21
22 of 4.19 (95% confidence interval 3.18-5.53) in the first 1-3 days after acute respiratory infection, with
23
24 the risk falling to baseline after 28 days¹⁹. Elderly people and those consulting for an infection judged
25
26 most likely to be due to influenza were at greatest risk. During the 2009 influenza pandemic people
27
28 with underlying cardiovascular disease were much more likely to be hospitalised¹³ and to die²⁰ from a
29
30 range of causes attributable to pandemic influenza. Although most deaths from H1N1pdm09 occurred
31
32 in younger people, this was partly a function of the age distribution of infections: in the UK the case
33
34 fatality rate in the elderly was much higher than in younger age-groups⁵ but overall numbers of deaths
35
36 were small as few elderly people were infected.
37
38
39
40
41
42
43
44
45
46

47 Various biological mechanisms are proposed to underlie a relationship between influenza or acute
48
49 respiratory infection and myocardial infarction²¹. Acute respiratory infections may result in a host of
50
51 acute inflammatory and haemostatic effects leading to systemic inflammation, altered plasma viscosity,
52
53 coagulability and haemodynamic changes²² as well as promoting local endothelial dysfunction, coronary
54
55
56
57
58
59
60

1
2
3 inflammation and plaque rupture²³. Immobility associated with bed-rest and dehydration might
4
5 potentiate these processes.
6
7
8
9

10 In conclusion, this study suggests that recent ILI occurring during the 2009 influenza pandemic was more
11
12 common in AMI patients. Taken in the context of previous work, this helps to support the hypothesis
13
14 that, as with other influenza strains, H1N1pdm09 could potentially trigger AMI in vulnerable groups. It
15
16 is likely, however, that the effect is not specific to influenza and could have also been due to other
17
18 viruses circulating at the time. The population impact of H1N1pdm09 on rates of hospitalisations and
19
20 deaths from myocardial infarction is also likely to have been relatively low given the mismatch between
21
22 the ages of those typically affected by H1N1pdm09 and acute coronary events as well as the relatively
23
24 mild clinical effects of this influenza strain.
25
26
27
28
29
30

31 **Acknowledgments**

32
33
34 We thank all patients who agreed to participate in this study and nurses on the cardiology and surgical
35
36 wards at the Royal Free Hospital who helped to identify potential participants. We acknowledge Mauli
37
38 Patel at the Royal Free Virology Laboratory who kindly processed, stored and tested samples.
39
40

41 **Contributors**

42
43
44 CWG conceived and designed the study, recruited participants, collected and analysed data and wrote
45
46 the manuscript. AMG, GH, RDR, LS and ACH assisted with study design. AMG provided laboratory
47
48 resources. CWG, AMG, RDR, LS and ACH interpreted results. AMG, GH, RDR, LS and ACH critically
49
50 revised the manuscript for intellectual content. LS and ACH provided supervision. All authors approved
51
52 the final version of the manuscript.
53
54
55
56
57
58
59
60

Funding statement

This work was funded by a Medical Research Council Clinical Research Training Fellowship for CWG, grant number G0800689. LS is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science, grant number 098504/Z/12/Z.

Competing interests statement

None declared

Data sharing statement

No additional data are available

References

1. Cox NJ, Subbarao K (1999) Influenza. *The Lancet* 354: 1277–1282.
2. Warren-Gash C, Smeeth L, Hayward AC (2009) Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. *The Lancet Infectious Diseases* 9: 601–610.
3. Swine influenza A (H1N1) infection in two children – Southern California, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 400–402.
4. Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 467–470.
5. Health Protection Agency (2010) Epidemiological report of pandemic (H1N1) 2009 in the United Kingdom: April 2009 - May 2010.
6. McLean E, Pebody RG, Campbell C, et al. (2010) Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol Infect* 138: 1531–1541.
7. Lagacé-Wiens PRS, Rubinstein E, Gumel A (2010) Influenza epidemiology – past, present, and future. *Crit Care Med* 38: e1–e9.
8. Chacko B, Peter JV, Pichamuthu K, et al. (2012) Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. *J Crit Care* 27: 106.e1–6.
9. Martin SS, Hollingsworth CL, Norfolk SG, et al. (2010) Reversible cardiac dysfunction associated with pandemic 2009 influenza A (H1N1). *Chest* 137: 1195–7.
10. Lee N, Chan PKS, Lui GCY, et al. (2011) Complications and Outcomes of Pandemic 2009 Influenza A (H1N1) Virus Infection in Hospitalized Adults: How Do They Differ From Those in Seasonal Influenza? *J Infect Dis* 203: 1739–1747.
11. Dawood FS, Iuliano AD, Reed C, et al. (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *The Lancet Infectious Diseases* 12: 687–695.

12. Khanom AB, Velvin C, Hawrami K, et al. (2011) Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care. *J Infect* 62: 52–58.
13. Campbell CNJ, Mytton OT, McLean EM, et al. (2010) Hospitalization in two waves of pandemic influenza A(H1N1) in England. *Epidemiology & Infection* 139: 1560–1569.
14. Lau LLH, Cowling BJ, Fang VJ, et al. (2010) Viral shedding and clinical illness in naturally acquired influenza virus infections. *J Infect Dis* 201: 1509–1516.
15. Rothbarth PH, Groen J, Bohnen AM, et al. *J Virol Methods* 78: 163–169.
16. Smeeth L, Thomas SL, Hall AJ, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine* 351: 2611–2618.
17. Clayton TC, Thompson M, Meade TW (2008) Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. *Eur Heart J* 29: 96–103.
18. Meier CR, Jick SS, Derby LE, et al. (1998) Acute respiratory-tract infections and risk of first-time acute myocardial infarction. *The Lancet* 351: 1467–1471.
19. Warren-Gash C, Hayward AC, Hemingway H, et al. (2012) Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. *J Infect Dis* 206: 1652–1659.
20. Mytton OT, Rutter PD, Mak M, et al. (2012) Mortality due to pandemic (H1N1) 2009 influenza in England: a comparison of the first and second waves. *Epidemiology & Infection* 140: 1533–1541.
21. Bazaz R, Marriott HM, Francis SE, et al. (2013) Mechanistic links between acute respiratory tract infections and acute coronary syndromes. *J Infect* 66: 1-17.
22. Harskamp RE, Van Ginkel MW (2008) Acute respiratory tract infections: a potential trigger for the acute coronary syndrome. *Annals of Medicine* 40: 121–128.
23. Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? *The Lancet* 349: 1391–1392.

Figure legends

Figure 1 Number of study participants admitted by influenza surveillance week compared to weekly ILI rates per 100,000 based on national RCGP surveillance data

Figure 2 Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory illness

Characteristic	Category	Cases (n=70)	Controls (n=64)	P value
Age group	40-49	8 (11.4)	13 (20.3)	0.61
	50-59	19 (27.1)	18 (28.1)	
	60-69	19 (27.1)	15 (23.4)	
	70-79	17 (24.3)	11 (17.2)	
	80+	7 (10.0)	7 (10.9)	
Gender	Female	13 (18.6)	15 (23.4)	0.49
	Male	57 (81.4)	49 (76.6)	
Admission month	September	8 (11.4)	7 (10.9)	0.92
	October	12 (17.1)	15 (23.4)	
	November	15 (21.4)	14 (21.9)	
	December	10 (14.3)	10 (15.6)	
	January	14 (20.0)	11 (17.2)	
	February	11 (15.7)	7 (10.9)	
Ethnicity	Asian or Asian British	18 (25.7)	6 (9.4)	0.03
	Black or Black British	2 (2.9)	0 (0.0)	
	Mixed	0 (0.0)	1 (1.6)	
	White	50 (71.4)	57 (89.1)	
BMI category	18.5-24.9	20 (30.8)	23 (39.0)	0.41
	25.0-29.9	36 (55.4)	24 (40.7)	
	30.0-39.9	8 (12.3)	10 (17.0)	
	40.0-max	1 (1.5)	2 (3.4)	
Smoker	No never	22 (31.4)	23 (35.9)	0.77
	Yes current	27 (38.6)	21 (32.8)	
	Yes ex	21 (30.0)	20 (31.3)	
Past medical history	Hypercholesterolaemia*	34 (48.6)	28 (43.8)	0.58
	Diabetes	14 (20.0)	12 (18.8)	0.86
	Hypertension	37 (52.9)	26 (40.6)	0.16
	AMI	14 (20.0)	5 (7.8)	0.04
	Stroke	1 (1.4)	4 (6.3)	0.14
Family history	AMI	43 (61.4)	19 (29.7)	<0.001
	Stroke	5 (7.1)	6 (9.4)	0.64
Influenza vaccination status [†]	Vaccinated	30 (42.9)	29 (45.3)	0.78

Table 1 Characteristics of study participants (n=134)

*28 cases (40%) and 25 controls (39%) with hypercholesterolaemia reported current statin use

[†]'Vaccinated' refers to receiving influenza vaccination in the current vaccination year (since September 2009).


Exposure variable	Prevalence – cases, n(%)	Prevalence – controls, n(%)	Unadjusted odds ratio (95% CI)	Adjusted odds ratio* (95% CI)
1. Respiratory illness	17 (24.3)	12 (18.8)	1.39 (0.60-3.19)	1.39 (0.56-3.47)
2. Influenza-like illness	10 (14.3)	3 (4.7)	3.39 (0.89-12.92)	3.17 (0.61-16.47)
3. Fever	11 (15.7)	4 (6.3)	2.80 (0.84-9.28)	2.42 (0.54-10.98)
4. Cough	21 (30.0)	10 (15.6)	2.31 (0.99-5.40)	2.04 (0.76-5.47)
5. Sore throat	10 (14.3)	8 (12.5)	1.17 (0.43-3.17)	1.43 (0.44-4.69)
6. Muscle ache	8 (11.4)	5 (7.8)	1.52 (0.47-4.92)	2.29 (0.59-8.92)
7. Influenza A IgA antibodies [‡]	25 (46.3)	28 (54.9)	0.71 (0.33-1.53)	0.82 (0.34-2.00)

Table 2 Odds ratios for the association between acute myocardial infarction and various respiratory illness exposure variables, unadjusted and adjusted

*Adjustments were made for age-group, gender, month of admission and influenza vaccination status (all exposures), family history of myocardial infarction (exposures 2, 3, 4 & 5) and personal history of myocardial infarction (exposures 2, 3, 4 & 5)

[‡]Note that n=105 (54 cases and 51 controls) for influenza antibodies where 8 equivocal results were excluded, compared to n=134 (70 cases and 64 controls) for all other exposures.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Number of study participants admitted by influenza surveillance week compared to weekly ILI rates per 100,000 based on national RCGP surveillance data
 150x90mm (300 x 300 DPI)

review only

1
2
3 **Title** Influenza-like illness in acute myocardial infarction patients during the winter wave of the influenza
4
5 A H1N1 pandemic in London: a case control study
6
7

8
9 **Authors** Charlotte Warren-Gash¹, Anna Maria Geretti², George Hamilton³, Roby D. Rakhit⁴, Liam
10
11 Smeeth⁵, Andrew C. Hayward¹
12
13

14 **Affiliations**

15
16
17 ¹Centre for Infectious Disease Epidemiology, Research Department of Infection & Population Health,
18
19 UCL, London, UK
20

21
22 ² Institute of Infection and Global Health, University of Liverpool, UK
23

24
25 ³ Department of Vascular Surgery, Royal Free London Foundation Trust, London, UK
26

27
28 ⁴ Department of Cardiology, Royal Free London Foundation Trust, London, UK
29

30
31 ⁵ Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical
32
33 Medicine, London, UK
34
35

36 **Corresponding author**

37
38 Dr Charlotte Warren-Gash

39
40 Research Department of Infection & Population Health

41
42 1st Floor, Royal Free Hospital

43
44 Rowland Hill Street

45
46 London NW3 2PF

47
48 Email: c.warren-gash@ucl.ac.uk / charlotte.warren-gash@doctors.org.uk
49
50

51
52
53 Tel: 020 7794 0500 x36720 Fax: 020 7794 1224
54

55
56 **Word Count** Abstract 296, main text 2505 (excluding article summary, tables, figures, legends and refs)
57
58
59
60

ABSTRACT

Objective: To investigate recent respiratory and influenza-like illnesses in acute myocardial infarction patients compared to patients hospitalised for acute non vascular surgical conditions during the second wave of the 2009 influenza A H1N1 pandemic

Design: Case control study

Setting: Coronary care unit, acute cardiology and acute surgical admissions wards in a major teaching hospital in London, UK

Participants: 134 participants (70 cases and 64 controls) aged ≥ 40 years hospitalised for acute myocardial infarction and acute surgical conditions between 21/09/2009 and 28/02/2010, frequency-matched for gender, 5-year age-band and admission week

Primary exposure: Influenza-like illness (ILI - defined as feeling feverish with either cough or sore throat) within the last month. **Secondary exposures:** Acute respiratory illness within the last month not meeting ILI criteria; nasopharyngeal and throat swab positive for influenza virus

Results: 29 participants of 134 (21.6%) reported respiratory illness within the last month, of whom 13 (9.7%) had illnesses meeting ILI criteria. The most frequently reported category for timing of respiratory symptom onset was 8-14 days before admission (31.0% of illnesses). Cases were more likely than controls to report ILI – adjusted OR 3.17 (95% confidence interval 0.61-16.47) – as well as other key respiratory symptoms, and were less likely to have received influenza vaccination – adjusted OR 0.46 (95% CI, 0.19-1.12) – although differences were not statistically significant. No swabs were positive for influenza virus.

Conclusions: Point estimates suggested that recent ILI was more common in patients hospitalised with acute myocardial infarction than with acute surgical conditions during the second wave of the influenza A H1N1 pandemic, and influenza vaccination was associated with cardio-protection, although findings were not statistically significant. The study was underpowered, partly because the age groups typically

1
2
3 affected by acute myocardial infarction had low rates of infection with the pandemic influenza strain
4
5 compared to seasonal influenza.
6
7
8
9

10 **ARTICLE SUMMARY**

11 **Article focus**

- 12 • Seasonal influenza can trigger cardiovascular complications but the cardiac effects of the 2009
13 influenza pandemic are less clear.
- 14 • We aimed to investigate recent influenza-like illness in patients hospitalised with acute
15 myocardial infarction and surgical conditions during the 2009 influenza pandemic in London.
16
17
18
19
20
21
22
23

24 **Key messages**

- 25 • 14.3% of patients hospitalised with acute myocardial infarction (cases) reported recent
26 influenza-like illness compared to 4.7% of patients hospitalised for acute surgical conditions
27 (controls)
28
- 29 • Cases were more likely than controls to report a range of recent respiratory symptoms and less
30 likely to have received influenza vaccination though differences were not statistically significant
31
32
- 33 • The median age of cases with acute myocardial infarction was 63.6 years, whereas the majority
34 of people infected with pandemic influenza strain nationally were young
35
36
37
38
39
40
41
42

43 **Strengths and limitations**

- 44 • The study was underpowered to detect an effect, partly due to low infection rates with the
45 pandemic influenza virus in age-groups typically affected by acute myocardial infarction, but it
46 will inform design of future similar studies
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Seasonal influenza can trigger cardiovascular complications and deaths in vulnerable populations, especially the elderly and those with underlying medical conditions¹. Evidence to support the hypothesis that seasonal influenza may trigger acute myocardial infarction comes from a range of observational studies incorporating the effects of different circulating influenza strains and subtypes². In a pandemic situation, however, when there is global spread of a novel influenza strain, clinical and demographic profiles of those affected may change dramatically.

The most recent influenza pandemic was caused by an influenza A H1N1 strain (H1N1pdm09) that emerged in Mexico and the United States in April 2009^{3,4}. The UK experienced several waves of infection with this novel strain - a first wave occurred in spring and summer 2009 followed by a second wave in the winter of 2009/10 and a post-pandemic wave in winter 2010/11⁵. Initial evidence from the first wave in the UK suggested that typical illnesses were mild and affected mainly children and young people⁶. The average age of cases increased over subsequent waves of the pandemic⁷ but it is unclear how this affected clinical illness profiles. Vaccination coverage did not reach high levels until the post-pandemic season.

There have been reports of myocarditis, myocardial injury and left ventricular systolic dysfunction, which may be reversible, in patients with severe H1N1pdm09^{8,9}. It has been suggested that H1N1pdm09 was associated with higher rates of extra-pulmonary complications than seasonal influenza¹⁰ but this is difficult to compare as surveillance of severe influenza-related disease was greatly enhanced during the pandemic. A recent mathematical modelling study estimated that globally there were 83,300 cardiovascular deaths associated with the first twelve months of H1N1pdm09 circulation in adults aged >17 years¹¹, but the contribution of myocardial infarction deaths to this figure is unknown.

1
2
3 In this study we aimed to investigate whether patients hospitalised for acute myocardial infarction
4 during the winter wave of the influenza A H1N1 pandemic were more likely than surgical patients to
5 have experienced recent influenza-like illness or acute respiratory illness, or to have concurrent PCR
6 positive influenza or evidence of influenza A IgA antibodies in sera.
7
8
9
10
11
12

13 **METHODS**

14 **Setting, design and participants**

15
16
17
18
19
20 This was an observational case control study carried out in hospital in-patients at the Royal Free London
21 NHS Foundation Trust between 21st September 2009 and 28th February 2010. Cases were patients aged
22 ≥ 40 years who had experienced an acute myocardial infarction (defined as a rise in troponin T with
23 ischaemic symptoms and/or typical ECG changes, or by angiographic evidence of acute coronary artery
24 thrombosis during primary percutaneous coronary intervention). Controls were patients aged ≥ 40 years
25 admitted with an acute surgical condition such as appendicitis, bowel or urinary obstruction and no
26 history of myocardial infarction within the past month. These patients were chosen as controls because
27 their admissions were considered unlikely to be influenced by recent influenza-like illness. Cases and
28 controls were frequency matched for gender, age-group in 5 year age-bands and week of admission. All
29 were English-speaking and able to provide written informed consent. The study size was based on
30 numbers of eligible patients hospitalised during the influenza circulation period.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 **Exposures**

47
48
49 The main exposure was recent influenza-like illness, defined as a history of feeling feverish with either
50 cough or sore throat within the last month. We also used the exposure recent acute respiratory
51 infection to capture a history of respiratory illness within the last month with any of the following
52 symptoms – fever, chills, dry cough, productive cough, myalgia, rhinorrhoea, blocked nose, sore throat,
53
54
55
56
57
58
59
60

1
2
3 wheeze, earache and fatigue – that did not meet criteria for influenza-like illness. Additional exposures
4
5 were nasopharyngeal and throat swabs testing positive for influenza by real-time polymerase chain
6
7 reaction (PCR), presence of IgA antibodies to influenza A in serum samples and self-reported influenza
8
9 vaccination status.
10

11 12 13 **Data sources and measurement**

14
15
16 We used a questionnaire to investigate recent respiratory and influenza-like illness as well as to capture
17
18 data on demographics, medical history and influenza vaccination status. Information on influenza
19
20 vaccination status was collected as 'vaccinated this year (from September 2009)', 'vaccinated last year
21
22 (September 2008 - August 2009)', 'vaccinated 2-5 years ago', 'vaccinated >5 years ago' and 'never
23
24 vaccinated'. Vaccination status was then re-categorised as a binary variable comprising 'vaccinated this
25
26 year' and 'unvaccinated', which included all other categories, to recognise that vaccinations in previous
27
28 seasons would not protect against the new circulating pandemic influenza strain. Medical records were
29
30 reviewed for details of the current admission and to confirm data on potential confounding factors.
31
32
33 Combined nasopharyngeal and throat swabs were taken from each participant, placed in viral transport
34
35 medium and transported to the laboratory for storage at -80°C. Samples were tested for the presence of
36
37 influenza virus RNA using a validated in house real-time PCR with a lower limit of detection of 1 RNA
38
39 copy per reaction, as previously described¹². A single serum sample was taken for quantification of IgA
40
41 antibodies to influenza A as a marker of recent exposure (as IgA levels peak at around 2 weeks after
42
43 exposure and reach baseline by around 4-6 weeks). Serum samples were centrifuged, frozen at -80°C
44
45 and batch tested using a commercially available enzyme-linked immunosorbent assay (EIA) for influenza
46
47 A IgA (Biosupply UK, cat no. RE56501). Antibody concentrations were initially explored as a continuous
48
49 variable, then categorised into 'positive' (>12 U/ml), 'equivocal' (8-12 U/ml) and 'negative' (>8 U/ml)
50
51 categories based on standard laboratory thresholds. Equivocal results were dropped for analyses.
52
53
54
55
56
57
58
59
60

Statistical methods

All analyses were carried out using Stata (*Stata Statistical Software: Release 12. College Station, TX: StataCorp LP*). Baseline comparability between cases and controls was assessed with χ^2 tests.

Characteristics of participants with and without missing data were also compared using χ^2 tests to assess any risk of bias associated with missing data. We used multivariable logistic regression analysis to investigate associations between recent influenza-like illness or acute respiratory illness exposures and case/ control status, controlling for the frequency-matching factors age-group, gender and month of admission and influenza vaccination status as an a priori confounder (all models) as well as for other potential confounding factors. An additional multivariable model in which influenza vaccination status was the main exposure was generated using the same approach. Potential confounders were examined using a backwards stepwise approach whereby factors independently associated with both exposure and outcome were included in models and likelihood ratio tests used to assess the effect of removing each one sequentially. If p values from likelihood ratio tests were <0.1 then factors were retained in the model.

RESULTS

Characteristics of study participants

134 participants were recruited, who comprised 70 cases from 106 approached (acceptance rate 66%) and 64 controls from 95 approached (acceptance rate 67%). Reasons for non-participation included lack of time, unwillingness to experience additional procedures and feeling tired or unwell. The median age of participants was 63.6 years (IQR 53.3-72.6) and 21% were female. Cases were more likely to be of Asian or Asian British ethnicity ($p=0.016$), to have a previous history of myocardial infarction ($p=0.04$) or a family history of myocardial infarction ($p<0.001$) than controls. Of the 70 patients hospitalised for acute myocardial infarction, 48 (68.5%) met criteria for ST-elevation myocardial infarction, 17 (24.3%)

1
2
3 had a non ST-elevation myocardial infarction and in 5 (7.1%) cases the subtype of myocardial infarction
4
5 was unspecified. Control patients were admitted with a range of acute non-vascular surgical
6
7 presentations that included colorectal, urological and orthopaedic conditions.
8
9

10
11 **Table 1**

12
13
14 **Timing of participants' admissions in relation to national influenza circulation**

15
16
17 A comparison of study participants' dates of admission with national rates of GP consultations for
18
19 influenza-like illness (ILI) based on RCGP surveillance data is shown in figure 1. The peak week for ILI
20
21 consultations in England was week 43 (ending 25th October 2009) when the rate was 42.8 per 100,000.
22
23 This was also the peak week for influenza virus circulation according to data from virological sentinel
24
25 surveillance schemes, when the proportion of positive samples reached 41.2%. Our recruitment period
26
27 spanned this period of peak influenza circulation.
28
29

30
31
32 **Figure 1**

33
34 **Recent respiratory and influenza-like illness**

35
36
37 17 cases (24.3%) and 12 controls (18.8%) reported respiratory illness in the month preceding hospital
38
39 admission. 13 illnesses – reported by 10 cases (14.3%) and 3 controls (4.7%) – met criteria for influenza-
40
41 like illness (defined as feeling feverish with cough and/or sore throat). The most frequently reported
42
43 category for the timing of respiratory symptom onset was 8-14 days before admission (31.0% of
44
45 illnesses). 4-7 days was the most frequently reported category for length of illness (37.9% of illnesses).
46
47 Symptom profiles of participants reporting recent respiratory illness are shown in figure 2. No swabs
48
49 tested positive for influenza virus nucleic acid. Serum samples were available on 113 of 134 participants
50
51 (84.3%). There were no significant differences in characteristics of participants with and without missing
52
53 serum samples (data not shown). 25 cases (43.1%) and 28 controls (50.9%) tested positive for serum
54
55
56
57
58
59
60

1
2
3 influenza A IgA antibodies. 62% of participants who were seropositive had received influenza
4
5 vaccination during the study period compared to 31% of seronegative participants. Overall 44.0% of
6
7 participants were vaccinated. The proportion of participants recruited in each month who were
8
9 vaccinated increased from 0% in September 2009, to 29.6% in October 2009, 44.8% in November 2009,
10
11 55.0% in December 2009, 72.0% in January 2010 and was 50% in February 2010.
12
13

14 15 16 **Figure 2**

17
18 Cases were more likely to have reported influenza-like illness than controls – adjusted OR 3.17 (95%
19
20 confidence interval 0.61-16.47) – as well as other key respiratory illness symptoms, although differences
21
22 were not statistically significant. Results from this logistic regression analysis are summarised in table 2.
23
24 There was also a trend towards a protective effect of influenza vaccination against myocardial infarction
25
26 – adjusted OR 0.46 (95% CI, 0.19-1.12) – after controlling for age-group, gender, month of admission and
27
28 personal history of AMI.
29
30
31
32

33 **Table 2**

34 35 36 **DISCUSSION**

37
38 The study was supportive of the hypothesis that recent respiratory and in particular influenza-like
39
40 illnesses occurring during the second wave of the influenza A H1N1 pandemic were more common in
41
42 patients hospitalised with acute myocardial infarction than with acute surgical conditions. Influenza
43
44 vaccination was also associated with protection against myocardial infarction, although differences were
45
46 not statistically significant. While we had hypothesised that more adults would be infected during the
47
48 second pandemic wave due to the expected upwards shift in age distribution of infections, national
49
50 rates of influenza-like illness remained low⁵, especially in age groups typically affected by acute
51
52 myocardial infarction. The study was therefore underpowered to detect an effect, partly due to limited
53
54 numbers of infections among participants.
55
56
57
58
59
60

1
2
3
4
5
6
7 Using self-reported recent respiratory and influenza-like illness as exposures introduced the possibility
8
9 of reporting or recall bias. Nonetheless this method allows greater sensitivity to detect recent
10
11 respiratory symptoms than relying on reports of medically attended illnesses, which comprise only a
12
13 small minority of influenza cases¹³. As cases and controls were frequency matched on week of
14
15 admission, external factors such as media coverage of the influenza pandemic should not have had a
16
17 differential effect on respiratory illness reporting. We chose to test both nasopharyngeal and throat
18
19 swabs to increase the sensitivity of virus detection. It was perhaps unsurprising, however, that none of
20
21 the nasopharyngeal and throat swabs was positive for influenza virus given a) the low rates of infection
22
23 in this age-group⁵ and b) that the majority of viral shedding in influenza occurs in the first 2-3 days after
24
25 symptom onset¹⁴ whereas most reported respiratory symptoms in study participants occurred 8-14 days
26
27 before admission. Based on our findings it seems unlikely that any delayed cardiac effect of influenza is
28
29 linked to ongoing or prolonged virus replication or shedding in the respiratory tract. Influenza serology
30
31 is difficult to interpret in vaccinated participants as it not possible to distinguish antibody rises caused by
32
33 infection from those caused by vaccination. Validation of the IgA assay used suggests it has acceptable
34
35 sensitivity and specificity to detect recent seasonal influenza A infection¹⁵ but its effect with the
36
37 pandemic strain H1N1pdm09 is unclear. It has previously been noted that serological studies carried out
38
39 during the 2009 influenza pandemic were severely hampered by cross reactivity both with vaccine and
40
41 with seasonal influenza strains⁷.

42
43
44
45
46
47
48
49
50 Previous observational studies using large electronic primary care databases have found an association
51
52 between GP consultation for acute respiratory infection in the last month and risk of acute myocardial
53
54 infarction¹⁶⁻¹⁸. Although studies were conducted over different time periods, they encompassed the
55
56 effect of varying seasonal influenza strains. **In the present study, we controlled for important potential**
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

confounders such as influenza vaccination status, and showed that statin use was equally prevalent in cases and controls. We did not, however, have complete data on other drugs that have been hypothesised to have immune-regulatory effects (such as ACE inhibitors ,angiotensin receptor blockers (ARBs), metformin, glitazones and fibrates). If these agents reduce the likelihood of people experiencing ILI and were more commonly used in cases than controls they could potentially have confounded the relationship between ILI and AMI. It was reassuring, however, that our results were consistent with those obtained in our recent self-controlled case series study - a design that implicitly controls for fixed confounders. In this study we used linked primary care and cardiac disease registry records from 3,927 patients from 2003-2009, which also included acute respiratory infection consultations occurring during the first wave of H1N1pdm09 circulation¹⁹. We found an incidence ratio for acute myocardial infarction of 4.19 (95% confidence interval 3.18-5.53) in the first 1-3 days after acute respiratory infection, with the risk falling to baseline after 28 days¹⁹. Elderly people and those consulting for an infection judged most likely to be due to influenza were at greatest risk. During the 2009 influenza pandemic people with underlying cardiovascular disease were much more likely to be hospitalised¹³ and to die²⁰ from a range of causes attributable to pandemic influenza. Although most deaths from H1N1pdm09 occurred in younger people, this was partly a function of the age distribution of infections: in the UK the case fatality rate in the elderly was much higher than in younger age-groups⁵ but overall numbers of deaths were small as few elderly people were infected.

Various biological mechanisms are proposed to underlie a relationship between influenza or acute respiratory infection and myocardial infarction²¹. Acute respiratory infections may result in a host of acute inflammatory and haemostatic effects leading to systemic inflammation, altered plasma viscosity, coagulability and haemodynamic changes²² as well as promoting local endothelial dysfunction, coronary

1
2
3 inflammation and plaque rupture²³. Immobility associated with bed-rest and dehydration might
4
5 potentiate these processes.
6
7
8
9

10 In conclusion, this study suggests that recent ILI occurring during the 2009 influenza pandemic was more
11
12 common in AMI patients. Taken in the context of previous work, this helps to support the hypothesis
13
14 that, as with other influenza strains, H1N1pdm09 could potentially trigger AMI in vulnerable groups. It
15
16 is likely, however, that the effect is not specific to influenza and could have also been due to other
17
18 viruses circulating at the time. The population impact of H1N1pdm09 on rates of hospitalisations and
19
20 deaths from myocardial infarction is also likely to have been relatively low given the mismatch between
21
22 the ages of those typically affected by H1N1pdm09 and acute coronary events as well as the relatively
23
24 mild clinical effects of this influenza strain.
25
26
27
28
29
30

31 **Acknowledgments**

32
33
34 We thank all patients who agreed to participate in this study and nurses on the cardiology and surgical
35
36 wards at the Royal Free Hospital who helped to identify potential participants. We acknowledge Mauli
37
38 Patel at the Royal Free Virology Laboratory who kindly processed, stored and tested samples.
39
40
41

42 **Contributors**

43
44
45 CWG conceived and designed the study, recruited participants, collected and analysed data and wrote
46
47 the manuscript. AMG, GH, RDR, LS and ACH assisted with study design. AMG provided laboratory
48
49 resources. CWG, AMG, RDR, LS and ACH interpreted results. AMG, GH, RDR, LS and ACH critically
50
51 revised the manuscript for intellectual content. LS and ACH provided supervision. All authors approved
52
53 the final version of the manuscript.
54
55
56

57 **Funding statement**

This work was funded by a Medical Research Council Clinical Research Training Fellowship for CWG, grant number G0800689. LS is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science, grant number 098504/Z/12/Z.

Competing interests statement

None declared

Data sharing statement

No additional data are available

References

1. Cox NJ, Subbarao K (1999) Influenza. *The Lancet* 354: 1277–1282.
2. Warren-Gash C, Smeeth L, Hayward AC (2009) Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. *The Lancet Infectious Diseases* 9: 601–610.
3. Swine influenza A (H1N1) infection in two children – Southern California, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 400–402.
4. Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009 (2009). *MMWR Morb Mortal Wkly Rep* 58: 467–470.
5. Health Protection Agency (2010) Epidemiological report of pandemic (H1N1) 2009 in the United Kingdom: April 2009 - May 2010.
6. McLean E, Pebody RG, Campbell C, Chamberland M, Hawkins C, et al. (2010) Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol Infect* 138: 1531–1541.
7. Lagacé-Wiens PRS, Rubinstein E, Gumel A (2010) Influenza epidemiology – past, present, and future. *Crit Care Med* 38: e1–e9.
8. Chacko B, Peter JV, Pichamuthu K, Ramakrishna K, Moorthy M, et al. (2012) Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. *J Crit Care* 27: 106.e1–6.
9. Martin SS, Hollingsworth CL, Norfolk SG, Wolfe CR, Hollingsworth JW. (2010) Reversible cardiac dysfunction associated with pandemic 2009 influenza A (H1N1). *Chest* 137: 1195–7.
10. Lee N, Chan PKS, Lui GCY, Wong BCK, Sin WWY, et al. (2011) Complications and Outcomes of Pandemic 2009 Influenza A (H1N1) Virus Infection in Hospitalized Adults: How Do They Differ From Those in Seasonal Influenza? *J Infect Dis* 203: 1739–1747.
11. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, et al. (2012) Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. *The Lancet Infectious Diseases* 12: 687–695.
12. Khanom AB, Velvin C, Hawrami K, Schutten M, Patel M, et al. (2011) Performance of a nurse-led paediatric point of care service for respiratory syncytial virus testing in secondary care. *J Infect* 62: 52–58.

13. Campbell CNJ, Mytton OT, McLean EM, Rutter PD, Pebody RG, et al. (2010) Hospitalization in two waves of pandemic influenza A(H1N1) in England. *Epidemiology & Infection* 139: 1560–1569.
14. Lau LLH, Cowling BJ, Fang VJ, Chan K-H, Lau EHY, et al. (2010) Viral shedding and clinical illness in naturally acquired influenza virus infections. *J Infect Dis* 201: 1509–1516.
15. Rothbarth PH, Groen J, Bohnen AM, De Groot R, Osterhaus AD (1999) Influenza virus serology – a comparative study. *J Virol Methods* 78: 163–169.
16. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, et al. (2004) Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine* 351: 2611–2618.
17. Clayton TC, Thompson M, Meade TW (2008) Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. *Eur Heart J* 29: 96–103.
18. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H, et al. (1998) Acute respiratory-tract infections and risk of first-time acute myocardial infarction. *The Lancet* 351: 1467–1471.
19. Warren-Gash C, Hayward AC, Hemingway H, Denaxas S, Thomas SL, et al. (2012) Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study. *J Infect Dis* 206: 1652–1659.
20. Mytton OT, Rutter PD, Mak M, Stanton E, Sachedina N, et al. (2012) Mortality due to pandemic (H1N1) 2009 influenza in England: a comparison of the first and second waves. *Epidemiology & Infection* 140: 1533–1541.
21. Bazaz R, Marriott HM, Francis SE, Dockrell DH (2013) Mechanistic links between acute respiratory tract infections and acute coronary syndromes. *J Infect* 66: 1-17.
22. Harskamp RE, Van Ginkel MW (2008) Acute respiratory tract infections: a potential trigger for the acute coronary syndrome. *Annals of Medicine* 40: 121–128.
23. Vallance P, Collier J, Bhagat K (1997) Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? *The Lancet* 349: 1391–1392.

Figure legends

Figure 1 Number of study participants admitted by influenza surveillance week compared to weekly ILI rates per 100,000 based on national RCGP surveillance data

Figure 2 Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory illness

Characteristic	Category	Cases (n=70)	Controls (n=64)	P value
Age group	40-49	8 (11.4)	13 (20.3)	0.61
	50-59	19 (27.1)	18 (28.1)	
	60-69	19 (27.1)	15 (23.4)	
	70-79	17 (24.3)	11 (17.2)	
	80+	7 (10.0)	7 (10.9)	
Gender	Female	13 (18.6)	15 (23.4)	0.49
	Male	57 (81.4)	49 (76.6)	
Admission month	September	8 (11.4)	7 (10.9)	0.92
	October	12 (17.1)	15 (23.4)	
	November	15 (21.4)	14 (21.9)	
	December	10 (14.3)	10 (15.6)	
	January	14 (20.0)	11 (17.2)	
	February	11 (15.7)	7 (10.9)	
Ethnicity	Asian or Asian British	18 (25.7)	6 (9.4)	0.03
	Black or Black British	2 (2.9)	0 (0.0)	
	Mixed	0 (0.0)	1 (1.6)	
	White	50 (71.4)	57 (89.1)	
BMI category	18.5-24.9	20 (30.8)	23 (39.0)	0.41
	25.0-29.9	36 (55.4)	24 (40.7)	
	30.0-39.9	8 (12.3)	10 (17.0)	
	40.0-max	1 (1.5)	2 (3.4)	
Smoker	No never	22 (31.4)	23 (35.9)	0.77
	Yes current	27 (38.6)	21 (32.8)	
	Yes ex	21 (30.0)	20 (31.3)	
Past medical history	Hypercholesterolaemia*	34 (48.6)	28 (43.8)	0.58
	Diabetes	14 (20.0)	12 (18.8)	0.86
	Hypertension	37 (52.9)	26 (40.6)	0.16
	AMI	14 (20.0)	5 (7.8)	0.04
	Stroke	1 (1.4)	4 (6.3)	0.14
Family history	AMI	43 (61.4)	19 (29.7)	<0.001
	Stroke	5 (7.1)	6 (9.4)	0.64
Influenza vaccination status [†]	Vaccinated	30 (42.9)	29 (45.3)	0.78

Table 1 Characteristics of study participants (n=134)

*28 cases (40%) and 25 controls (39%) with hypercholesterolaemia reported current statin use


[†]'Vaccinated' refers to receiving influenza vaccination in the current vaccination year (since September 2009).

Exposure variable	Prevalence – cases, n(%)	Prevalence – controls, n(%)	Unadjusted odds ratio (95% CI)	Adjusted odds ratio* (95% CI)
1. Respiratory illness	17 (24.3)	12 (18.8)	1.39 (0.60-3.19)	1.39 (0.56-3.47)
2. Influenza-like illness	10 (14.3)	3 (4.7)	3.39 (0.89-12.92)	3.17 (0.61-16.47)
3. Fever	11 (15.7)	4 (6.3)	2.80 (0.84-9.28)	2.42 (0.54-10.98)
4. Cough	21 (30.0)	10 (15.6)	2.31 (0.99-5.40)	2.04 (0.76-5.47)
5. Sore throat	10 (14.3)	8 (12.5)	1.17 (0.43-3.17)	1.43 (0.44-4.69)
6. Muscle ache	8 (11.4)	5 (7.8)	1.52 (0.47-4.92)	2.29 (0.59-8.92)
7. Influenza A IgA antibodies [‡]	25 (46.3)	28 (54.9)	0.71 (0.33-1.53)	0.82 (0.34-2.00)

Table 2 Odds ratios for the association between acute myocardial infarction and various respiratory illness exposure variables, unadjusted and adjusted

*Adjustments were made for age-group, gender, month of admission and influenza vaccination status (all exposures), family history of myocardial infarction (exposures 2, 3, 4 & 5) and personal history of myocardial infarction (exposures 2, 3, 4 & 5)

[‡]Note that n=105 (54 cases and 51 controls) for influenza antibodies where 8 equivocal results were excluded, compared to n=134 (70 cases and 64 controls) for all other exposures.



Percentage of cases (n=70) and controls (n=64) reporting various symptoms during respiratory illness
150x90mm (300 x 300 DPI)

Review only

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation	Reported on page no.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	5
		(b) For matched studies, give matching criteria and the number of controls per case	Frequency matching criteria given on p5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-7
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	Study size based on numbers of eligible patients hospitalised during the influenza circulation period
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6-7
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how matching of cases and controls was addressed	N/A

		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	Data not systematically collected but reasons for non-participation include lack of time and feeling unwell during admission
		(c) Consider use of a flow diagram	Not done as no follow up with this study design. Fig 1 shows recruitment over time.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1 and p8
Outcome data	15*	Report numbers in each exposure category, or summary measures of exposure	8
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	6
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	12

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.